THE PATENT ELIGIBILITY RESTORATION ACT-RESTORING CLARITY, CERTAINTY, AND PREDICTABILITY TO THE U.S. PATENT SYSTEM

Senate Judiciary Committee Senate October 8, 2025

Official record ↗ · Linked to the scheduled hearing

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

[Senate Hearing 119-282]
[From the U.S. Government Publishing Office]

 S. Hrg. 119-282

 THE PATENT ELIGIBILITY
 RESTORATION ACT-RESTORING CLARITY,
 CERTAINTY, AND PREDICTABILITY
 TO THE U.S. PATENT SYSTEM

=======================================================================

 HEARING

 before the

 SUBCOMMITTEE ON INTELLECTUAL 
 PROPERTY

 OF THE

 COMMITTEE ON THE JUDICIARY
 UNITED STATES SENATE

 ONE HUNDRED NINETEENTH CONGRESS

 FIRST SESSION
 __________

 OCTOBER 8, 2025
 __________

 Serial No. J-119-44
 __________

 Printed for the use of the Committee on the Judiciary

 [GRAPHIC NOT AVAILABLE IN TIFF FORMAT]
 
 
 www.judiciary.senate.gov
 www.govinfo.gov
 
 ______
 
 U.S. GOVERNMENT PUBLISHING OFFICE

62-725 WASHINGTON : 2026 
 
 
 
 
 
 
 
 
 COMMITTEE ON THE JUDICIARY

 CHARLES E. GRASSLEY, Iowa, Chairman
 
LINDSEY O. GRAHAM, South Carolina RICHARD J. DURBIN, Illinois, 
JOHN CORNYN, Texas Ranking Member
MICHAEL S. LEE, Utah SHELDON WHITEHOUSE, Rhode Island
TED CRUZ, Texas AMY KLOBUCHAR, Minnesota
JOSH HAWLEY, Missouri CHRISTOPHER A. COONS, Delaware
THOM TILLIS, North Carolina RICHARD BLUMENTHAL, Connecticut
JOHN KENNEDY, Louisiana MAZIE K. HIRONO, Hawaii
MARSHA BLACKBURN, Tennessee CORY A. BOOKER, New Jersey
ERIC SCHMITT, Missouri ALEX PADILLA, California
KATIE BOYD BRITT, Alabama PETER WELCH, Vermont
ASHLEY MOODY, Florida ADAM B. SCHIFF, California

 Kolan Davis, Chief Counsel and Staff Director
 Joe Zogby, Democratic Chief Counsel and Staff Director
 

 Subcommittee on Intellectual Property

 THOM TILLIS, North Carolina, Chair
 
MICHAEL S. LEE, Utah ADAM B. SCHIFF, California, 
MARSHA BLACKBURN, Tennessee Ranking Member
ERIC SCHMITT, Missouri SHELDON WHITEHOUSE, Rhode Island
KATIE BOYD BRITT, Alabama CHRISTOPHER A. COONS, Delaware
ASHLEY MOODY, Florida MAZIE K. HIRONO, Hawaii
 PETER WELCH, Vermont

 Geoff MacLeay, Republican Chief Counsel
 Maher Bitar, Democratic Chief Counsel
 
 
 
 
 
 
 
 
 C O N T E N T S

 ---------- 

 OPENING STATEMENTS

 Page
Tillis, Hon. Thom................................................ 1
Schiff, Hon. Adam B.............................................. 3

 WITNESSES

Blaylock, Richard................................................ 24
 Prepared statement........................................... 40
 Responses to written questions............................... 122
Caltrider, Steven................................................ 26
 Prepared statement........................................... 49
 Responses to written questions............................... 130
Cohen, Mark...................................................... 5
 Prepared statement........................................... 57
 Responses to written questions............................... 135
Iancu, Andrei.................................................... 7
 Prepared statement........................................... 73
 Responses to written questions............................... 151
Kappos, David.................................................... 9
 Prepared statement........................................... 82
 Responses to written questions............................... 161
Lemon, Mike...................................................... 10
 Prepared statement........................................... 90
 Responses to written questions............................... 166
Peschin, Sue..................................................... 28
 Prepared statement........................................... 108
 Responses to written questions............................... 173
Salsberg, Corey.................................................. 29
 Prepared statement........................................... 112
 Responses to written questions............................... 178

 APPENDIX

Items submitted for the record................................... 189

 
 THE PATENT ELIGIBILITY
 RESTORATION ACT-RESTORING CLARITY,
 CERTAINTY, AND PREDICTABILITY
 TO THE U.S. PATENT SYSTEM

 ---------- 

 WEDNESDAY, OCTOBER 8, 2025

 United States Senate,
 Subcommittee on Intellectual Property,
 Committee on the Judiciary,
 Washington, DC.
 The Subcommittee met, pursuant to notice, at 2:30 p.m., in 
Room 226, Dirksen Senate Office Building, Hon. Thom Tillis, 
Chair of the Subcommittee, presiding.
 Present: Senators Tillis [presiding], Blackburn, Moody, 
Schiff, Coons, and Hirono.

 OPENING STATEMENT OF HON. THOM TILLIS, 
 A U.S. SENATOR FROM THE STATE OF NORTH CAROLINA

 Chair Tillis. The Chair will come to order. Just for 
housekeeping, before I do my opening statement, we are going to 
have votes beginning at, I believe, somewhere between now and 
2:45. I have instructed the cloakroom, unless my vote is needed 
to break a tie, that I don't intend to recess the hearing, so 
we will charge through, but if I have to leave, it is in fact 
because I need to break a tie. I don't anticipate that, and I 
know that you all put a lot of work into this preparation, and 
I want to show you the utmost respect for not having your 
testimony and these discussions be interrupted.
 Today, we discuss a topic that I think, in my time here, 
has been often confused and mischaracterized, and I actually 
believe it is one of the most important issues facing our 
country today, and I should say, in the patent community. It is 
the topic of patent eligibility reform. The long overdue need 
for patent eligibility reform is one that, if left unaddressed, 
will cede America's, I believe cede America's well-earned title 
of the global innovation leader and global intellectual 
property rights leader to other communities, can't let that 
happen. And under my watch, which incidentally is over the next 
452 days, it will be one of my top priorities in my office.
 The sad part about the potential loss of our, what I 
believe, championship status in the IP and intellectual 
property protection community is foreign governments like the 
CCP are actively working to undermine our IP system, and they 
are attempting to overtake America's position as the global IP 
leader, as I said before.
 There are those in this country who, rather than fix the 
problem, would like to take advantage of ambiguity or, you 
know, the comfort with the status quo that's been created 
because of the confusing and I think sometimes conflicting 
outcomes in our courts.
 Now, we have four relatively recent Supreme Court decisions 
that have caused patent eligibility law in the U.S. to be 
confused, constricted, and unclear. That is what we are trying 
to fix here, folks. It has led to inconsistent lower court 
decisions, uncertainty in innovation, uncertainty in investment 
communities, and unpredictable business outcomes, all things 
that, if you know me, I don't like.
 Research has confirmed that, under the expanded judicial 
exceptions, U.S. inventors are unable to obtain patents in 
areas where economic peers offer protections. This is 
particularly concerning in the economically critical areas of 
biotechnology and computer-implemented invention where patent 
restrictions decrease investment and sink capital overseas.
 As of 2021, all 12 then-sitting judges of the U.S. Court of 
Appeals, of the Federal Circuit Court lamented the State of the 
current law. I have always said that we should not rush to 
legislate and that we should let courts do their job until they 
don't, and that's where we are now.
 Case in point, in 2021, I worked with former USPTO Director 
David Kappos, who we will hear from today, and retired judge 
Paul Mischel to file an amicus brief in the American Axle case. 
I was disappointed to see the Supreme Court decline the 
opportunity to offer clarity on patent eligibility, so we still 
have a lot of work ahead of us.
 And while former USPTO Director Iancu, Andre Iancu, who 
also we will hear from today, made great strides with the 2019 
PEG, the Revised Patent Subject Matter Eligibility guidance, it 
changed how patent examiners review patents, but the guidance 
is not binding on the courts, and when patents are challenged 
in litigation, the guidance lacks the force and effect of law.
 That is why I have introduced the Patent Eligibility 
Restoration Act of 2025, or PERA, along with Senator Coons. 
Earlier this year, I was happy to see Senators Blackburn and 
Senators Hirono join as co-sponsors. PERA preserves the first 
part of the current eligibility statute, but it eliminates 
overly broad set of three current judicial exceptions, 
replacing them with five specific, defined statutory 
exclusions. By eliminating and replacing the current judicial 
exceptions, PERA provides predictable patent eligibility for 
important computer-implemented technology developments and 
medical advances, creating a solid background for America's 
innovation future.
 It is important to note that patent eligibility and 
patentability are often conflated. This is a tool that 
opponents to patent eligibility reform, I think, often leverage 
to sow confusion and paint the narrative that expanding patent 
eligibility will equate to rampant and uncontrolled 
patentability. I disagree.
 Section 101 was not intended to function as a gatekeeper to 
keep out ineligible patent claims. Patent eligibility is simply 
one step in the process of determining patentability. Should a 
patent examiner find a claim invention fails to meet one or 
more of the requirements outlined under Sections 101, 102, 103, 
and 112, a patent will not be issued.
 Simply meeting the requirements of Section 101 does not 
mean that a patent will be granted. I will remain a champion 
for strong, reliable, and predictable intellectual property 
rights and for inventors and creators, large and small. And as 
part of that promise, I will not stop shining a spotlight on 
the need for patent eligibility reform.
 I am also heartened to say that our current USPTO director, 
John Squires, shares this understanding and that we need patent 
eligibility reform and that the status quo is not sufficient. 
This is no more evidenced than by his ceremonial signing of two 
patents last month on technology generally considered not to be 
eligible under Section 101.
 I hope that this is our last IP Subcommittee hearing on 
this topic and that we will soon move to PERA and a markup in 
this Congress.
 I have already stated all my opening comments. I want to 
give Adam, Senator Schiff, an opportunity to make opening 
comments, and then we will also hear from Senator Coons.
 Senator Schiff.

 OPENING STATEMENT OF HON. ADAM B. SCHIFF, 
 A U.S. SENATOR FROM THE STATE OF CALIFORNIA

 Senator Schiff. Chairman Tillis, thank you for bringing us 
together for this important hearing on patent eligibility. As I 
do not have a Tillis rule, and as I am a freshman, I will be 
running off to vote. And as I have a resolution that may come 
up this afternoon, depending on where Senator Tillis is on that 
resolution, I may ask you to keep him here, especially if he is 
the decisive vote.
 The right to patent inventions is enshrined in Article I, 
Section 8, Clause 8 of our Constitution. Even back in 1787, the 
Framers knew it was important to prioritize and protect 
innovation. Over 200 years later, their foresight has cemented 
the United States as the worldwide leader in innovation. The 
Constitution grants inventors the exclusive right to their 
respective discoveries for a limited period of time. On that 
point, everyone agrees. Where experts, stakeholders, Members of 
Congress often disagree is exactly what qualifies as a 
discovery.
 Thomas Jefferson believed that any new or useful art, 
machine, manufacturer, or composition of matter or any new or 
useful improvement thereof was eligible for a patent. In 1952, 
when Congress recodified Jefferson's original language, they 
swapped the word ``art'' for ``process'' in what we now 
recognize as Section 101 of the Patent Act.
 In Diamond v. Chakrabarty, the Supreme Court recognized 
Congress' intention for anything under the sun that is made by 
man to be patentable. Yet the Court also wrote that ``This is 
not to suggest that Section 101 has no limits or that embraces 
every discovery.'' The Supreme Court has long recognized 
explicit limits on patent eligibility. Laws of nature, physical 
phenomenon, abstract ideas are not eligible for patent. The 
first miner to discover gold in the earth could not patent the 
mineral, and the first person to find an apple in the wild 
could not patent the fruit. And I speak with some authority on 
that matter as I am Adam and I am married to a woman named Eve. 
If you could patent the first apple found in the wild, we would 
own that patent. Simile Einstein couldn't patent e=mc\2\, and 
yes, my wife is actually named Eve. Einstein couldn't patent 
e=mc\2\, Archimedes could not patent pi, Pythagoras could not 
have patented the Pythagorean theorem. The courts have long 
held that these discoveries are manifestations of nature, free 
to all men and reserved exclusively to none.
 While it is important to have clearly established 
exceptions and guidelines around patent eligibility, many 
inventors, patent attorneys, and even judges on the Federal 
Circuit, where the appeals court of jurisdiction, which is the 
appeals court of jurisdiction for patent cases, have bemoaned 
the current state of the law as muddled and unclear. Four 
Supreme Court cases in the 2010's, Alice, Mayo, Bilski, and 
Myriad, have collectively created uncertainty around the 
patentability of various technological and medical innovations.
 In the middle of the artificial intelligence technological 
revolution, clarity and stability around the proper 
interpretation of Section 101 is necessary to ensure that 
America continues to win the international innovation race. It 
is equally important that biotechnology companies have clarity 
as they work to invent lifesaving medical diagnostic tests and 
other treatments.
 As Members of Congress, we must ensure that we are striking 
the right balance. If algorithms or technological inventions 
that simply duplicate preexisting processes on a computer or on 
a chip are patented, it could have the reverse effect of 
stifling innovation rather than encouraging it. Similarly, if 
one company is able to monopolize a medical diagnostic test 
without guardrails, that could lead to less patients receiving 
proper treatment as opposed to more. It is our job to figure 
out the proper balance between encouraging investments in 
innovation and ensuring that as many Americans are able to reap 
the benefits of that innovation as possible.
 I look forward to hearing our witnesses today and learning 
more about the current state of patent eligibility law in the 
United States. I look forward to exploring the steps that we as 
Members of Congress can take to bring much-needed clarity to 
the law. And I want to express my gratitude again for Chairman 
Tillis and Senator Coons for taking on this extremely important 
but complex issue.
 And I yield back.
 Chair Tillis. Thank you, Senator Schiff.
 Welcome to the witnesses, and thank you for the time that 
you have put into preparing for the hearing. I will introduce 
you all and then give you an opportunity for opening 
statements.
 Mr. Cohen serves as the senior technology fellow at the 
Asia Society of Northern California and at the Asia Society 
Policy Institute located here in Washington, DC. Mr. Cohen 
previously served as the first USPTO representative in China 
and as USPTO senior counsel. In total, Mark has 40 years of 
private, public sector, in-house, and academic experience in 
China.
 Director Andrei Iancu serves as a partner at Sullivan & 
Cromwell LLP and is a former undersecretary of commerce for IP 
and director of the U.S. Patent and Trademark Office. Mr. Iancu 
has decades of experience representing plaintiffs and 
defendants in IP matters across the technical scientific 
spectrum. While director of the USPTO, he established the 2019 
Patent Eligibility Guidance, which made great initial strides 
at providing clarity in the eligibility space.
 Mr. Kappos serves as a partner at Cravath, Swaine, and 
Moore LLP and is former Undersecretary of Commerce for IP and 
Director of U.S. Patent and Trademark Office. Mr. Kappos covers 
a wide range of complex IP issues, including those pertaining 
to blockchain, crypto assets, and fintech, as well as 
cybersecurity and data privacy. As Director of the USPTO, he 
led the agency in re-engineering its entire management and 
operational systems, as well as an engagement with the global 
innovation community.
 I get really excited when you do things like the entire 
management and operational systems. That is what I used to do 
for a living, Mr. Kappos. Thank you for doing it for the USPTO.
 And Mr. Lemon serves as vice president of legal affairs at 
the National Retail Federation. Mr. Lemon oversees Federal, 
legislative, and regulatory advocacy on a wide range of IP and 
commerce issues. Earlier in his career, Mr. Lemon spent nearly 
7 years with the U.S. Senate Judiciary Committee, serving under 
Senator Mike Lee. Welcome, Mr. Lemon.
 Mr. Cohen, we will start with you and go down the aisle or 
down the desk.

STATEMENT OF MARK COHEN, SENIOR TECHNOLOGY FELLOW, ASIA SOCIETY 
OF NORTHERN CALIFORNIA, SENIOR FELLOW, UNIVERSITY OF AKRON LAW 
 SCHOOL, ALEXANDRIA, VA

 Mr. Cohen. Okay. Thank you very much, Mr. Chairman, Ranking 
Member, and Members of the Subcommittee.
 Chair Tillis. By the way, before I get started, I should 
say it is at the Chairman's discretion to swear you in. I 
generally don't swear you into these Committees, and a lot of 
that has to do with all of the feedback that we get back later 
on. I know you are going to be honest, and all the people 
watching, either here in the room or on C-SPAN, are going to 
take you to task if you go too far off strategy.
 So now you can start, Mr. Cohen.
 Mr. Cohen. Thank you. I feel much better now, thank you.
 Thank you for inviting me to testify on patent eligibility 
issues. I applaud the Committee's efforts to look at other 
markets, such as China, in evaluating the need for PERA. 
Needless to say, the opinions expressed here are my own.
 My point today is that the United States has created 
uncertainty in its rules on patent-eligible subject matter 
during a period where China has steadily broadened and 
clarified its laws. This divergence has been to China's 
distinct advantage. Since the Chinese Patent Law's passage in 
1984, China has amended its patent law four times. Between 
revisions, it has used detailed guidelines, pilot programs, and 
local experiments to continuously adapt to new technologies and 
challenges. In other words, China has continuously used the 
patent law as a tool for technological catchup and competitive 
advantage.
 In the USA, judicial decisions, which were just noted, have 
produced an eligibility test that is vague, unpredictable, and 
inconsistently applied since the period from 2010 to 2014. The 
Patent Office has tried to provide clarity with guidelines, but 
it cannot overcome judicial interpretations. Courts, the PTAB, 
and the USPTO reach inconsistent outcomes. Entire industries, 
particularly in such areas as diagnostics and software, face 
higher uncertainties, including risks of patent invalidation. 
These developments have had documented long-term impacts.
 We have been living through a natural experiment for the 
past dozen years since the Supreme Court narrowed eligibility. 
During this same period, China has expanded eligibility in 
emerging technologies through bright-line technical solution 
tests, producing a surge in filings and investment, both 
domestic and foreign. This divergence lets us compare outcomes 
under different legal regimes and shows that eligibility rules 
are not merely academic. They shape national competitiveness.
 How has China moved to expand eligibility? In 1992, it 
added pharmaceutical protection that had previously been 
excluded. Human diagnostic methods, which are statutorily 
ineligible, can be redrafted into allowable product claims. In 
2019 and again in 2024, China updated its guidelines to broaden 
protection in software, AI, big data, and even stem cell 
research. Examiners are told to consider the claim as a whole 
and focus on the technical solution. This approach in general 
makes patenting more predictable.
 AI patent growth underscores these differences. In China, 
AI patent filings grew from roughly 59,000 in 2019 to nearly 
189,000 in 2024, more than tripling in 5 years. By comparison, 
U.S. patent filings during the same period were essentially 
flat between 31 and 35,000 annually. During this same time, 
CNIPA, that is Chinese Patent Office, has also twice revised 
its examination guidelines to make clear that computer-executed 
information processing methods remain patent eligible and to 
emphasize the requirement of a technical solution. In the 
United States, AI patents remain vulnerable to unpredictable 
abstract idea challenges under Alice, although despite their 
low number, they do tend to have a higher citation value on the 
U.S. side.
 Diagnostics during COVID provide a further cautionary tale. 
Since the Supreme Court's decision in Mayo, the Federal Circuit 
has held that virtually every diagnostic method claim to be 
ineligible. Empirical analysis has concluded that in the 4-
years following Mayo, venture capital investment in diagnostic 
technologies in the U.S. was nearly $9.3 billion lower than it 
would have been otherwise.
 As another example, although American innovators filed many 
COVID-related diagnostic applications, eligibility uncertainty 
discouraged commercialization and private investment. The 
United States thus entered the recent pandemic with stronger 
support for vaccines than for diagnostics.
 Another point concerns retroactivity. In the U.S., patents 
obtained in good faith can later be invalidated under new 
judicial standards. In China, by contrast, the law presumes 
against retroactivity while permitting retroactivity in narrow 
cases to enhance rights. This stability also encourages longer-
term investments in key aspects.
 My lesson is not that we should copy China. Rather, we need 
to recognize how our competitors use their patent systems 
strategically, including to benefit their own industries and 
encourage investment. If our rules remain unclear, there is 
also the risk that investment and jobs will migrate from the 
USA to China or to other markets. I join Andrei Iancu in urging 
Congress also to provide active oversight of how eligibility 
standards are implemented, not limited only to patenting but 
also to the full range of commercial and security consequences.
 PERA restores clear statutory baselines, preserves 
exclusions for laws of nature and mental processes, and removes 
unnecessary unpredictability. Importantly, PERA does not weaken 
other grounds of invalidity. Patents may still be found to be 
not new, non-useful, obvious, not enabled, et cetera. PERA 
ensures that eligibility is restored to its limited threshold 
role. By passing a carefully worded PERA and by exercising 
ongoing congressional oversight, this Committee will send a 
strong message that the U.S. intends to maintain a reliable, 
competitive, and predictable patent system, one that attracts 
investment, supports commercialization, and strengthens 
American's leadership in the global innovation economy.
 Thank you, and I look forward to your questions.
 [The prepared statement of Mr. Cohen appears as a 
submission for the record.]
 Chair Tillis. Thank you, Mr. Cohen.
 Mr. Iancu, before you get started, Senator Coons, would you 
like to make any comments before we move on with introductions?
 Senator Coons. Thank you very much, Chair Tillis.
 Let me just simply say more broadly that finding bipartisan 
agreement on patent reform is a critical undertaking for this 
Subcommittee, for the Committee as a whole. I am grateful to 
continue on this journey with Senator Tillis with whom we held 
a hearing on this exact subject I think with 45 witnesses now 
quite a few years ago.
 So thank you for your engagement, for your testimony today. 
Thank you to the Chair and Ranking of the Subcommittee for your 
continued engagement, and let's work together to try and help 
clear the thicket of Section 101 jurisprudence.
 Chair Tillis. Thank you, Senator Coons. Director Iancu.

 STATEMENT OF ANDREI IANCU, PARTNER, SULLIVAN & CROMWELL LLP, 
 FORMER UNDERSECRETARY OF COMMERCE FOR IP AND DIRECTOR OF THE 
 U.S. PATENT AND TRADEMARK OFFICE, LOS ANGELES, CA

 Mr. Iancu. Thank you, Chairman Tillis, Ranking Member 
Schiff, and Members of the Subcommittee. Thank you for another 
opportunity to discuss PERA and the urgent need to bring 
clarity to Section 101 of the patent code. I want to begin by 
commending Chairman Tillis and Senator Coons for their 
leadership in reintroducing PERA and staying with this issue 
over so many years, as well as Senators Blackburn and Hirono 
for cosponsoring the bill and this Subcommittee for once again 
taking up the critically important task of modernizing, as 
Senator Tillis mentioned, one of the most fundamental 
provisions of our patent laws.
 After more than a decade of confusion and inconsistent 
court rulings, only Congress can resolve the uncertainty that 
threatens investment, innovation, and America's competitive 
edge. I want to focus most of my remarks on the critical and 
immediate need for Congress to act.
 The categories of patentable subject matter outlined in 
Section 101--any new and useful process, machine, manufacture 
or composition of matter--were first listed in the Patent Act 
of 1793, as Senator Schiff mentioned when Jefferson and Madison 
were writing law, and have remained largely unchanged for more 
than 230 years. Yet, the technologies that power today's 
economy were unimaginable back then.
 As a result, courts and agencies have struggled to map 18th 
century text onto 21st century innovation, resulting in a 
confusing, contradicting, and ultimately innovation-destroying 
patchwork of decisions and exclusions that Congress never 
enacted. Article 1, Section 8, Clause 8 of the Constitution 
grants Congress the power to promote the progress of science 
and useful arts by securing for limited times to authors and 
inventors the exclusive right to their respective writings and 
discoveries.
 So here is the crux of the problem. While patents are for 
the useful arts, courts have lost sight in many cases of what 
the useful arts include exactly. Are medical diagnostic tests 
to be included? How about artificial intelligence algorithms? 
How about advanced data processing that is so central to the 
information age? For many inventions in these and other areas, 
the answer is at best unclear. And at worst, some decisions 
exclude such critical technologies from the patent system 
altogether, such as medical diagnostics. This is untenable.
 I often say that patents are the currency of innovation. 
Patents incentivize innovation, they enable investment in that 
innovation, and they facilitate the transfer of that innovation 
to the market and the commerce surrounding it. But like any 
currency, the patent system depends on predictability and 
stability and cannot fluctuate on the whim of every new court 
or patent office decision.
 Some argue that the status quo works for them. Sure, chaos 
and uncertainty can benefit the few who are able to exploit it. 
But for the innovation economy at large, for the United States, 
chaos and uncertainty in the patent system is deadly. At scale, 
the uncertainty caused by the current state of the law on 
Section 101 is increasing legal and transaction costs and 
decreasing investment in new technologies, especially advanced 
technologies that require significant funds and time to 
develop. In turn, this is pushing innovation in such areas to 
other countries, diminishing our competitive edge and opening 
the door, as Mr. Cohen so ably mentioned, to our most fearest 
competitors to take the lead in the critical technologies of 
the future.
 The world is at an inflection point for innovation. We are 
on the cusp of tremendous advances of remarkable new 
technologies such as artificial intelligence, biotechnologies, 
quantum biotechnology, quantum computing, and so much more. Yet 
the American innovation system has a hand tied behind its back 
with antiquated and unpredictable laws in this area. I urge 
Congress to clarify the law and unleash once again the great 
American innovative spirit.
 I commend the Subcommittee once again for holding this 
hearing and continuing the debate toward modernizing Section 
101, and thank you again for the opportunity to testify, and I 
look forward to your questions.
 [The prepared statement of Mr. Iancu appears as a 
submission for the record.]
 Chair Tillis. Thank you. Director Kappos.

STATEMENT OF DAVID KAPPOS, PARTNER, CRAVATH, SWAINE, AND MOORE 
 LLP, FORMER UNDERSECRETARY OF COMMERCE FOR IP AND DIRECTOR OF 
 THE U.S. PATENT AND TRADEMARK OFFICE, NEW YORK, NY

 Mr. Kappos. Yes, good afternoon, Chairman Tillis, Ranking 
Member Schiff in absentia, and Members of the Subcommittee on 
Intellectual Property. Thank you for the opportunity to testify 
today. I am testifying solely on my own behalf.
 I also thank new USPTO Director Squires, who in his first 
week in office took a stand in favor of broad patent 
eligibility not once but twice. It is encouraging to see the 
administration and the USPTO recognizing that patent 
eligibility in the U.S. is broken and aligning with broad 
eligibility as the solution.
 The U.S. is living with doctrinal chaos in patent 
eligibility. Over the past decade plus, stakeholders have 
endured a roller coaster of shifting rules with decisions that 
contradict one another and defy planning. When innovators can't 
rely on predictable eligibility rules, investment pulls back, 
R&D stalls, and opportunities are lost. That is the opposite of 
what a patent system is supposed to do.
 The consequence? We are driving valuable innovation into 
trade secrecy. When eligibility is unpredictable, the rational 
response is don't disclose, keep it in the vault. This marks an 
alarming return to practices not seen since the Middle Ages. 
When our courts shut the door on entire categories of 
invention, we drive inventors back to a closed-door mentality 
that impedes knowledge-sharing and advancement.
 This concern is not merely theoretical. It is happening 
now. Firms are opting to protect innovation via trade secrets 
rather than patents. WIPO statistics between 2013 and 2023 
revealed that the number of patent applications filed in the 
USPTO when controlling for increasing applications from China 
has decreased 2.5 percent. So in the era of 101 doctrinal 
chaos, the PRC is propping up a U.S. patent system that 
Americans themselves are avoiding.
 The solution, PERA, applies three simple principles. If an 
invention fits within statutory eligibility categories and has 
specific practical utility, it is eligible. Non-technological 
subject matter is expressly excluded so no one can patent 
economic practices or wedding ceremonies. Eligibility becomes 
the gate, and the rigorous tests of Sections 102, 103, and 112 
do the rest.
 To be clear, restoring broad eligibility is not about 
allowing patents on ideas or bad patents or stifling basic 
research. It is about restoring coherence so that like 
inventions are treated alike, investors can underwrite risk, 
examiners can reach principled results when reviewing patent 
applications, and courts can adjudicate on stable footing. 
Under a reformed Section 101, every invention must still meet 
the stringent tests of novelty, non-obviousness, and full 
disclosure. Weak or overbroad patents would still be rejected 
but for the right reasons, not through an unpredictable, 
distorted Section 101.
 A reformed Section 101 would also enable the USPTO to 
provide its examiners with stable, well-grounded examination 
guidance, which has proven impossible under the current 
framework. In the absence of clear law, the USPTO has resorted 
to shifting guidance, lacking lasting clarity, causing patents 
issued under one set of guidelines to become invalid under the 
next. With clear statutory foundation, the USPTO can provide 
consistent and legally compliant guidance for innovators and 
patent examiners.
 Now, I appreciate concerns about unintended consequences 
such as frivolous patents or litigation abuse, but Congress 
fixed those problems with the AIA, and recent data shows that 
the USPTO is doing a good job preventing the issuance of weak 
patents. The risk, the greater risk lies in inaction. If we do 
nothing, we continue under a regime that virtually no one 
thinks is working. Even those who benefit from the current 
doctrinal chaos cannot defend it as clear and practicable.
 I will end with a simple truth. Innovation that is never 
realized because our system failed to encourage it is an 
incalculable loss. We cannot afford such losses. PERA will 
prevent them and strengthen our innovation economy.
 Mr. Chairman, thank you again for the opportunity to share 
my thoughts.
 [The prepared statement of Mr. Kappos appears as a 
submission for the record.]
 Chair Tillis. Thank you. Mr. Lemon.

 STATEMENT OF MIKE LEMON, VICE PRESIDENT, LEGAL AFFAIRS, 
 NATIONAL RETAIL FEDERATION, WASHINGTON, DC

 Mr. Lemon. Chairman Tillis, Ranking Member Schiff, and 
Members of the Subcommittee, thank you for the opportunity to 
testify today. I am here on behalf of the National Retail 
Federation and as co-chair of United for Patent Reform, which 
represents Main Street and other businesses of every kind, 
retailers, restaurants, banks, realtors, hotels, autos, and 
service providers that together employ more than 90 million 
Americans, two-thirds of the private workforce.
 Retailers have benefited enormously from innovation, and we 
value a strong patent system. Retailers routinely license and 
pay for valid patents. What we cannot sustain is a return to 
vague, abstract patents that create no new technology and serve 
only as the basis for litigation.
 With many bills, we have to speculate what the world would 
look like if the bill were to pass. In this case, we know what 
the world would look like because we have already seen it. 
Before the Supreme Court's Alice decision, patent trolls 
targeted retailers for ordinary, everyday practices. Companies 
were sued for having online shopping carts, emailing receipts, 
or putting maps on websites. None of these were real 
inventions. They were simply the routine ways of doing business 
adapted to new technology. Yet the cost of defending even one 
of these cases could be millions of dollars, and for many small 
and mid-sized retailers, that meant settling claims just to 
survive.
 This problem follows a familiar cycle. Each time a new 
technology emerges, opportunists rush to repackage ordinary 
practices as if they were inventions. First came the computer 
wave, where routine tasks were suddenly claimed as novel 
because they were ``done on a computer.'' Then came the 
internet wave, where those same practices were said to be 
inventive simply because they were ``done on the internet.'' 
The same thing happened with smartphones. Now we are seeing the 
beginnings of a fourth wave, patents that claim routine 
business functions that are ``done with AI.'' None of these 
waves created new technology. They created lawsuits.
 The Alice decision restored balance, allowing courts to 
throw out weak patents early and stopping years of wasteful 
litigation. The result was that retailers could adopt new 
technologies with confidence. Trolls brought fewer cases, and 
hundreds of bad patents were invalidated. Most importantly, 
real innovation did not suffer. Investments in e-commerce, 
apps, and digital tools has only grown since Alice.
 PERA would undo that progress. It would reverse Alice and 
170 years of settled case law, bringing back the very patents 
that created chaos in the first place. Proponents of PERA argue 
that Alice created uncertainty, but the evidence shows 
otherwise. In reality, it is PERA that would create uncertainty 
by sweeping away decades of settled law.
 The impact would be felt across Main Street and ultimately 
by consumers. Before Alice, even a small business using an off-
the-shelf reservation system or a simple online portal could be 
threatened with a patent lawsuit. After Alice, many of those 
cases disappeared. If PERA is enacted, they will return. And 
every dollar businesses spend fighting frivolous lawsuits is a 
dollar they cannot put toward lowering prices, hiring staff, or 
improving service. For consumers, PERA would act like a hidden 
tax, raising costs at a time when American families can least 
afford it.
 To be clear, Main Street still has a patent troll problem. 
More than half of all patent litigation this last year was from 
patent trolls. And with the recent weakening of the PTAB at the 
PTO and an increase in anonymous third-party litigation 
funding, that problem has been getting worse.
 Allow me to give you a recent example of the patents that 
caused problems for Main Street that Alice addressed. An LLC 
called Cascades Branding has a patent filed in 2007 that claims 
the following. A company logo appears on a device, the user 
taps the logo, the device identifies the user's location, and 
then it shows nearby stores for that brand on a map. For nearly 
14 years, more than 30 Main Street businesses were sued for 
infringing this patent, including Lowe's, Chipotle, Target, 
Hallmark Cards, GameStop, Capital One, Best Buy, Marriott, and 
Aldi. Only recently did the Federal Circuit finally strike it 
down under Alice. That decision protected retailers and 
consumers from many more years of wasteful litigation. If PERA 
passes, patents like this one will come roaring back.
 On behalf of retailers, auto manufacturers, bankers, home 
builders, hotels, realtors, restaurants, startups, tech, and 
telecom, I urge the Subcommittee to preserve the balance and 
fairness that Alice established and to reconsider moving 
legislation that would take us backward.
 Thank you, and I look forward to your questions.
 [The prepared statement of Mr. Lemon appears as a 
submission for the record.]
 Chair Tillis. Thank you, Mr. Lemon.
 I should have mentioned, most of you all have been in 
Committees that I have Chaired before. I see Mr. Blaylock 
already getting his notes ready for the second panel. But I do 
a kind of a debate club format, so if any of you want to 
challenge an assertion or a comment that was made in any of the 
opening statements, I will give you an opportunity to do that.
 But since Senator Coons is here, I am going to let him go 
ahead with his questions in case he needs to go back to another 
vote.
 Senator Coons. No, I am fine. Thank you so much for your 
real and sustained partnership in this important area, Senator 
Tillis.
 Mr. Lemon just asserted that Alice did not create chaos. In 
fact, Alice produced certainty, protection from widespread 
lawsuits based on weaker or improvidently granted patents and 
predicted that if PERA were to be adopted, a whole new wave of 
patents would be improvidently granted, sort of AI applied to 
any typical business practice, and we would return to a period 
of widespread poor-quality patents. As former PTO directors, 
Mr. Kappos, Mr. Iancu, any response, any comment? Is that how 
you view Alice? And is that why you think PERA would be 
valuable or invaluable? I would just be interested in engaging 
with the argument he just made.
 Mr. Kappos. Yes, well, thank you for the question, Senator 
Coons. So a couple of----
 Chair Tillis. If I may interrupt, Senator Coons, I am a 
tie-breaking vote on a Committee matter not on the floor, so I 
have got to go break a tie, and I will be back.
 Senator Coons. Fabulous.
 Chair Tillis. If Senator Coons hasn't completely exhausted 
you all by the time I have gotten back, then we will stand in 
recess until I return if that is okay.
 Senator Coons. Okay. I will exhaust them.
 Chair Tillis. Thank you.
 [Laughter.]
 Mr. Kappos. Thank you for the question, Senator Coons. So, 
you know, a couple of comments. First, none of us wants low-
quality patents or inappropriate untoward assertions of low-
quality patents against retailers or anyone else, so we are all 
aligned around patent quality. PERA would expressly exclude 
``do it on a computer'' patent claims or ``do it on AI'' patent 
claims. So in respect of that problem, which I would agree with 
Mr. Lemon was a problem in the past, PERA would make absolutely 
no change in the law. Those claims were inappropriate. They are 
ineligible, and they will remain ineligible under PERA.
 Senator Coons. Why?
 Mr. Kappos. Because PERA includes language that expressly 
says adding ``wrote computer'' or similar recitation to do it 
on a computer or do it on AI----
 Senator Coons. Does not create eligibility.
 Mr. Kappos. Right, does not confer eligibility.
 But one other comment that I would make, you know, relative 
to the--you know, the case law has settled down and the case 
law is working fine, it is not working fine at all. And you 
don't have to go any further back than decisions from just the 
last couple of years in the Yu v. Apple case and then following 
it in Contour IP Holdings, two cases, both about identical 
concepts, use of dual sensors in cameras in order to improve 
acuity of photography. The first one, Yu v. Apple, goes to one 
panel of the Federal Circuit that finds the claims to be 
abstract and ineligible. The second one, Contour Holdings, goes 
to a different panel of the Federal Circuit. Identical 
technology, right? It is indistinguishable. That second 
different panel finds the claims to be technological and 
perfectly eligible. So the law isn't settling down. It 
continues to be hopelessly confused.
 Senator Coons. In fact, if I understand correctly, a 
majority of the Federal Circuit has asked Congress to step in 
and clarify the jurisprudence in this area.
 Mr. Kappos. That is correct. In fact, every single judge on 
the Federal Circuit, all 12 of them as of 2021, if I remember 
right, decried and essentially begged Congress and/or the 
Supreme Court to come in and clarify the law.
 Senator Coons. Pretty striking.
 Director Iancu.
 Mr. Iancu. Yes. Look, I agree with what Director Kappos 
just mentioned. Let me just emphasize a particular point in 
response to Mr. Lemon's testimony. Mr. Lemon is primarily 
concerned with what he called vague patents that protect no new 
innovation. And certainly, I agree that we don't want vague 
patents. We don't want patents that are not on new innovation 
and the like, no debate there, dispute there at all. We 
certainly don't want frivolous lawsuits, you know, on patents 
that shouldn't have been granted and so on.
 But those are different questions from eligibility. It is a 
very important fundamental point to understand the distinction 
between eligibility and patentability. Just because something, 
some technology is eligible for patent does not mean that the 
patent office should grant a patent after all this examination 
is finished through all of the statutory requirements. If we 
see an application with vague claims, those should be rejected 
under Section 112 that specifically require claims to be 
claimed with particularity. If we see claims on something that 
is not new, those should be rejected under Section 102 that 
require novelty. Or even if they are obvious, they should be 
rejected under 103, you know, which require applications or 
claims to be non-obvious.
 The problem we have had over the past several years is that 
courts have conflated these various statutory schemes. And I 
suspect that the variety of concerns and the patents that Mr. 
Lemon addresses as concerning to his members, if there is a 
problem with them, that could be addressed under the other 
Sections of the law.
 Senator Coons. As I believe you explained to me many years 
ago, Director Iancu, 101 was meant to be a very coarse filter, 
and then each of those successive provisions of the Patent Act 
to be finer filters that say obviousness or particularity. And 
the current jurisprudence has conflated those and has reached 
back to 101 to invalidate patents that could or should have 
been invalidated under other tests.
 Mr. Iancu. That is correct. And because of this confusion--
because we are applying concepts such as newness to Section 101 
for eligibility or concepts of vagueness, which should be 
Section 102, we were applying those to Section 101, we have 
lost track as a result of the real tests that have to be 
applied under the proper statutory framework.
 Look, examiners of the PTO and courts know how to do a 
novelty analysis under 102 or an obviousness analysis under 
103. They know how to do a vagueness analysis under 112. Those 
over many years, decades of precedent, that type of analysis is 
well-established. What gets confusing is when you are supposed 
to do these types of analysis under 101 when there is no 
framework established for doing that analysis, and you don't 
need it because you have these other statutory schemes.
 Senator Coons. Thank you.
 Mr. Cohen, my sense is that you testified about how 
innovation isn't possible without strong patent protection and 
how uncertainty in the law of patent eligibility threatens 
innovation in a way that actually creates a national security 
threat. Help me understand--I missed your opening statement; I 
apologize--what you see as the national security threat and why 
that particularly is focused on or heightened by the lack of 
clarity on patent eligibility jurisprudence.
 Mr. Cohen. Well, you know, these days people more and more 
are conflating trade issues, IP issues, and national security 
issues and sometimes a little bit too generously, but I think 
in this area there are genuine national security concerns. When 
we are talking about emerging technologies, there is a 
significant overlap with technologies where there are patent 
eligibility issues. And in recent years, we have seen a great 
more of civil-military fusion, that is civil technologies that 
can be rapidly adopted to military applications. Drones, for 
example, you can go play with them in a park or they can be a 
tool for warfare.
 So the ability to obtain patents in technologies where it 
is fruitful to disclose, but it provides a leg up for the 
innovator, perhaps also to innovate in the security context as 
well, is critical to develop the revenue stream to support that 
kind of R&D activity. That's just, you know, another aspect of 
having an effective patent system that they have in emerging 
technologies that can have a national security application.
 Senator Coons. Have you seen innovators, companies, abandon 
patenting in the U.S. system and instead seeking patent 
protection in China or Japan or the EU?
 Mr. Cohen. Well, you know, Adam Mossoff's article is 
probably the leading article on this. He has identified, I 
think, about 1,300 or so patents that were granted in the EU 
and/or China that were denied in the U.S. on eligibility 
issues. And there is also other anecdotal information on 
specific patents.
 Whether we have seen migration of investment from the U.S. 
to China or migration of talent, it is a little bit harder 
because there really isn't that much research, frankly, on this 
topic. There is Adam's research. There is Robert Taylor who 
interviewed investors in startup enterprises, and he was 
looking at the availability of patents, and he found that 
across technological sectors, software diagnostics and other 
areas. And there is also other survey data that has been out 
there on this topic.
 Senator Coons. Mr. Iancu, Mr. Kappos, you served as PTO 
directors in different administrations of the two parties, yet 
you seem to have reached the same conclusion, certainly with 
regards to supporting PERA. Should that surprise me at all? Can 
you explain how you came to the same conclusions, perhaps by 
different routes?
 Mr. Iancu. Well, one of the beautiful things about patent 
law, Senator Coons, is that it is nonpartisan or bipartisan. 
It's one of the, it's probably one of the last areas.
 Senator Coons. Maybe the only area.
 [Laughter.]
 Mr. Iancu. Maybe it is the only area. And in reality, we 
guard that jealously. We are very proud of being in a system 
that is not driven by politics, bipartisan politics. But look, 
we've both, I believe, seen the same thing.
 Another way to look at it is that I am primarily a 
litigator. And from a litigation perspective, I can see the 
problems that the unpredictability causes the parties. It 
causes unpredictability for both parties, for the patent owner 
and the accused infringer. When lawyers have a difficult time 
telling their clients with reasonable certainty what the 
outcome is more likely than not to be, that increases the 
likelihood of litigation. It lengthens the likely span of a 
particular lawsuit, makes it more difficult to reach a 
settlement or a resolution because, you know, one side's 
lawyers is going to have a very different view than the other 
side's lawyers, given that for every Section 101 decision out 
there, there is an equal and opposite Section 101 decision, as 
Mr. Kappos' gave, example he gave in his testimony.
 So from a litigation perspective--and I will defer to 
Director Kappos from a transactions perspective or other 
areas--but from a litigation perspective for sure, I have 
definitely come to the belief for a long time now, it was one 
of the main reasons I wanted to go to the patent office some 
years ago, was to try to address this issue and try to bring 
some clarity.
 Senator Coons. Mr. Kappos, in the transaction perspective, 
is it your sense that this has driven down investment in 
several different frontier technology areas in the United 
States, the lack of certainty, the litigation risk, the 
inability to say, yes, if we invest more in this field, we will 
be able to get a patent, and we will be able to defend it, and 
thus, we will be able to achieve a certain market progress?
 Mr. Kappos. Yes, that is exactly right, Senator Coons. And 
I will give you a few examples. So in my practice, which is 
very much transactional, so helping investment to come to great 
ideas, whether it is in an academic to small-company context or 
large-company context, what I hear and what I have to advise in 
connection with eligibility is if you can avoid the patent 
system, avoid it because it is not predictable, it is not 
dependable.
 So I will give you a couple of quick examples. Wealthy 
investors from North Carolina seeking advice on investing in a 
great company making retrofitting automobiles with crash 
avoidance systems based on patents. When I looked at them, I 
quickly assessed extremely vulnerable to Section 101, so my 
advice had to be invest in this company and make them grow if 
they have got great leadership, if they have got great trade 
secrets, if they have got network effects, but I cannot advise 
you to make an investment based on their patent position 
because it is very, very vulnerable. Result, no investment, 
company goes out of business. That is absolutely what happens.
 One other quick example in another field, you know, in New 
York where I normally live and work, meeting with venture 
investors and private equity funds. And in those rooms, right, 
they will move very quickly once they are told by lawyers that 
an invention is likely to be ineligible for patent protection 
or a patent is likely to be invalid.
 And again, as a quick vignette, I was taken aside by a 
managing director at a private equity fund after we had a long 
meeting about eligibility for patent protection. And he said, 
listen to me, Sonny, my job is simple. When I leave the office 
at the end of the day, I have to have more money for my 
investors than I had at the beginning of the day. And if you 
smart people can help me do that by virtue of a strong and 
effective and reliable patent system that you can tell me 
produces eligible inventions that can be patented, fine. He 
said, otherwise, I am going to invest in pork bellies. And 
these are guys who move billions of dollars. So you can 
imagine, right, those meetings are happening all over the 
country, and they are not good for this eligibility discussion.
 Senator Coons. That is a lot of pork bellies.
 Last question, if I might, Mr. Lemon, because I have given 
everyone else a chance, you may not agree with PERA, but are 
there other bills you think Congress could or should take up 
and pass that would help strengthen our IP system?
 Mr. Lemon. I appreciate the question, Senator. Retailers in 
Main Street, as I said, are very invested in the success of the 
patent system. And while we may disagree on some of the 
proposals that have come out of the Subcommittee, we do think 
that there are areas where lots of work can be done. In the 
area of third-party litigation funding, we see a lot of 
significant concerns there among all our broad membership. We 
would love to see the Committee talk more about that.
 We have issues on the retailer side with customer stays 
that sometimes are denied in cases where we think that they 
should be approved, and so we are interested in talking about 
proposals to help make sure that there is a presumption of a 
customer stay when the manufacturer steps in to take the case.
 So I think there are lots of areas where we can work 
together to improve the health of the system.
 Senator Coons. Thank you. And thank you to all the panel 
members.
 Thank you, Senator Tillis.
 Chair Tillis. Senator Coons, I want the record to reflect 
that this 65-year-old made it to the Capitol and back, cast 
three tie-breaking votes in less than 10 minutes.
 Senator Coons. You are, as ever, overperforming.
 Chair Tillis. And I am looking forward to getting a readout 
on the questions that Senator Coons offered.
 I was in a discussion about a month ago with someone who is 
very focused on trade policy and actually very supportive of 
the administration's current posture on trade policy. I have 
some reservations in some areas, generally okay with what he is 
doing, but what I found interesting about this discussion with 
this economist--he made the comment that, well, you know, I am 
looking at this purely through the lens of the aperture as a 
trade expert. Of course, I am not taking into account 
geopolitical factors and other things that may influence--you 
know, may require you to throttle back on one policy or another 
because it is not just about a discrete transaction.
 I feel the same way here. I feel that some who may be 
opposed to what we are trying to do with PERA are not realizing 
that I am not only trying to work on patent eligibility, but I 
am also trying to counter geopolitical threats. And so that has 
to be a key driver for me. It can't just be about the atomic 
considerations within the retail industry. That is important to 
me, of course, and it is not lost on me how important the 
industry is nationally and in North Carolina, but I also have 
to account for future threats that could ultimately even affect 
the retail industry if we don't get it right, if we lose our 
innovation advantage.
 So, Mr. Cohen, I want to start with you. Let's say that 
this just is a nonstarter, doesn't get done. You know, the 800-
pound gorilla is China. Tell me what the future looks like and 
what we stand to lose if we just allow ourselves to fall into 
second or third place as an innovation economy.
 Mr. Cohen. Well, this is the issue that keeps me up at 
night. And unfortunately, the data we have does not suggest 
that the current direction is going positively. I mean, the 
Australian Strategic Policy Institute did a study that showed 
that China was dominating in roughly 90 percent of all the 
critical technologies. ITIF here in Washington has also done a 
study in different sectors which also showed Chinese dominance. 
China is also increasingly coming to a position where they are 
not only a follower of other countries, but they plan on making 
their own policies in their own interests, which is to be 
expected.
 And in areas where there are critical technologies, which 
China owns, which we are well aware of, like in electrical 
vehicle batteries or in pharma, where China has become an 
important outbound licensor, they have also taken positions 
that they are not going to share their technology. China is not 
going to replace the U.S. China's going to be its own model for 
the world as a dominant technological power. That may involve 
less sharing, at least with the developed world, and a greater 
focus on critical technologies.
 We also are in an era of decreased transparency with China, 
so the ability to gauge how well foreigners, particularly 
Americans, are being treated, I could say that after observing 
this for 40 years, I know less today than 5 or 10 years ago 
because China aggressively curates its cases, and I can't tell 
you how Americans fare before the courts in China. I have my 
suspicions, but I really cannot tell you because the cases are 
not transparent. So this is a great unknown in many respects.
 The other and final point I would like to make is that 
China believes in IP. Now, many people in the U.S. do not, many 
people in Congress may not, but they view IP as of strategic 
importance and important to enhancing their own power and 
prestige and capacity to innovate and attracting talent and 
whatever else you can add on to that. And they have taken steps 
to aggressively improve their system in their own interests.
 I think there is an assumption here that since it is so 
difficult to protect IP in China, China has no IP system. Well, 
they have roughly a half a million court cases each year on 
intellectual property, which is several multiples of the U.S. 
docket. They have specialized trial courts in intellectual 
property and appellate courts, and they have 5-year plans on 
intellectual property. After all, they are a socialist economy, 
so they are trying to leverage that in their own interests of 
strategically advancing and becoming a technological 
superpower.
 And, I think, to get back to your question, if we are 
looking at 5 or 10 years out, unless we dramatically improve 
our capacity for oversight and evaluating China's capacity for 
technological improvement, it will be very difficult to see 
where we will land, but it will not be a good place.
 Chair Tillis. I am going to turn to Senator Schiff. I am 
going to ask some other questions.
 Senator Schiff, I actually had to leave, go break three 
ties, and come back, so I am going to be here for the duration, 
but I will go ahead and let you ask questions, and I will ask 
afterwards.
 Senator Schiff. All right. Thank you, Chairman.
 In 2024, USPTO issued guidance on patent eligibility to 
help examiners and stakeholders evaluate whether AI-related 
inventions are eligible. Late last month, Director John Squires 
issued an opinion signaling even stronger support for AI-
related inventions, clearing the Section 101 threshold.
 Mr. Kappos, let me start with you. I would be interested in 
your thoughts on what AI-related inventions you believe should 
be eligible for a patent, what AI-related inventions you think 
should not be eligible. Is there a risk that allowing every AI-
related invention to be patented could stifle innovation? And 
how do we ensure that the Patent Office strikes the right 
balance?
 Mr. Kappos. Well, thank you, Senator Schiff, for the 
question. So first of all, I would tell you that I applaud the 
recent changes made to the USPTO's eligibility guidelines by 
Director Squires, and I think also Deputy Director Coke Morgan 
Stewart before Director Squires got into his job. I think that 
they lend additional clarity and expansiveness to eligibility 
for AI-related inventions.
 I would echo some of the examples that you gave earlier, 
Senator Schiff, in terms of where the limits should be. 
Mathematical algorithms, mathematical formulas, e=mc\2\, pi, 
things like that, not eligible. They never were. They wouldn't 
be under PERA. They shouldn't be, even if implemented or 
somehow related to AI. But practical applications of them, use 
in advancing computer technology, broadly stated, absolutely 
should be eligible, and the much more suited tests of Sections 
102, novelty; 103, obviousness; and 112, written description, 
are the tests that always did and should be returned to their 
role of doing the heavy lifting to determine what gets patented 
and what doesn't.
 Senator Schiff. Well, thank you. Let me turn, if I can, to 
the diagnostic test issue. Mr. Cohen, you made a compelling 
argument regarding the lack of patentability and therefore the 
lack of investment. I would be curious whether any of you want 
to share a counterargument. What is the case to be made for the 
lack of patentability? Is this just the courts getting it 
wrong? Is there a different balance that should be struck? What 
are the tradeoffs here?
 Mr. Kappos. Happy to start with that, Senator Schiff, and 
it is a great question. So, look, we all care about ourselves 
and our loved ones getting access to medical diagnostics. That 
is super important, and we all care about those diagnostics 
being appropriately priced, and we are all upset when they are 
not appropriately priced. So I think, you know, broad agreement 
that pricing and diagnostics needs to be reasonable and fair.
 But pricing is a very different issue from patent 
eligibility. Patent eligibility is about whether the diagnostic 
exists in the first place, whether the cure is there to be 
priced at some price. Once the cure is there, once the patent 
system has done its job and broad eligibility has incented 
research and development and moving that through the FDA 
clinical approval process to make a diagnostic or drug 
available, fine, we should have very tough discussions about 
pricing, but we need to put them in totally different 
categories because the diagnostic that doesn't exist because 
the incentives weren't there might as well be priced at 
infinity.
 Senator Schiff. Anyone have a different view?
 Mr. Iancu. No, but I don't, but I suspect on the next panel 
you will find at least one witness who does. But Senator, one 
point I want to add to what Director Kappos just said is the 
bottom line is currently de facto under the court rulings, 
various court rulings, there are no patents on diagnostic 
techniques in the United States. And one has to ask who made 
that decision? If the United States decides not to protect by 
patent such a huge area of, an important area of technology, it 
seems to me that that needs to be subject to debate in this 
body and decision in a democratic way in this body. That is 
why, in my view, it is so important for Congress to return to 
legislating here where it hasn't done any since 1793 to address 
issues just like this.
 My personal view and all my testimony today is just my own 
personal capacity is that diagnostics are critically important 
technology, and we want to incentivize innovation in that area 
and investment in that area to bring more and more such new 
techniques that cure patients, treat patients, and overall 
increase improve the human condition. That is my view. And for 
that, you need to have patent eligibility in that space. And 
again, that doesn't mean that you are going to grant patents to 
all of those applications. You still have to make sure that the 
application, the invention is new, non-obvious, precise enough, 
and so on. But at least from an eligibility point of view, I 
don't think Congress has ever said that the United States 
should exclude that area of technology.
 Senator Schiff. Thank you, Chairman.
 Chair Tillis. Director Iancu, you covered one matter in 
answer to Senator Schiff's question about why we should be 
legislating. PERA relies on language that some have suggested 
as undefined or that should, I guess, be left to others. I 
think there are two terms that I want you to specifically talk 
about, and that's the terms ``substantially'' and 
``practically.'' Why are those problematic?
 Mr. Iancu. Well----
 Chair Tillis. Why should it be argued that they are 
problematic?
 Mr. Iancu. ``Substantially'' and ``practically'' that 
appear in the bill you are asking about, right?
 Chair Tillis. Yes.
 Mr. Iancu. Well, so the question--the concern folks express 
is that those are vague terms that will be subject to 
litigation, and they're new terms in PERA and would have to be 
eventually decided by a court as to what they mean. If folks 
don't like that those terms, then they should propose something 
else. Those terms appear in the bill with respect to business 
methods. You know, it says that the process that is 
substantially economic--financial, business, social, cultural, 
et cetera--should not be, should not be eligible. That is in 
Section (b)(1)(B) of the bill. So that's, that is the concern. 
To be frank, we have to see if that actually adds to the 
uncertainty that folks are so concerned about, and if it does, 
I am sure the courts would resolve it fairly quickly.
 What I would say is that the main approach of PERA, and I 
believe the correct approach, is to identify categories which, 
on their own--or as the bill says, ``as such''--are not covered 
by the Patent Act, are therefore not in the useful arts. And 
Senator Schiff mentioned a few of them in his opening remarks 
such as pure mathematical formulas, ``as such''; pure laws of 
nature, gravity, apple falls from the tree and hits Newton in 
the head by itself, you just can't get a patent on gravity, 
``as such.'' Same thing with pure financial transactions.
 But as soon as they are incorporated into a practical 
application that is technological, then that should become 
eligible. That's what we tried to say in 2019 with the patent 
eligibility guidelines. That is what PERA does as well. So 
whether or not we have the term ``substantially'' in there does 
not affect that particular issue, as long as we clearly define 
what pure categories on their own, ``as such'', are out, and 
how they would come back in, under what combinations to become 
practical. Then, I think the bill adds much clarity.
 Chair Tillis. Thank you.
 Director Kappos.
 Mr. Kappos. Senator Tillis----
 Chair Tillis. You can add to that. I was going to ask you a 
question too, but if you would like to add to that first, go 
ahead.
 Mr. Kappos. Well, yes, just in the spirit of the debate 
club, so just to----
 Chair Tillis. Yes, and Mr. Lemon, you will probably want to 
pay attention to the question I am going to have for Mr. 
Kappos.
 Mr. Kappos. Just to add, so in a patent system that 
accommodates all manner of technology, there are some things 
that are going to be matters of degree, right, not matters of 
kind. And the words ``substantially'' and ``practically'' 
accommodate that. They put in the hands of factfinders and 
adjudicators of law, judges, some amount of discretion to be 
able to exercise judgment. That's what those words are about. 
There is no way to have a patent system and a set of laws 
around a patent system that accommodates and leads to fair 
results across all of the issues that come up without having 
some requirement for judgment on degrees, right? So something 
that is substantially in the business domain, yes, that is 
going to require some amount of judgment by judges at points. 
And, you know, practically about a business method or not is 
going to require some judgment to be applied by judges.
 But the other extreme--or there are two other extremes, one 
which is randomness that we are living with now, right, which 
we are all here because that is not very helpful. And the other 
one is rigid rules that result in bad decisions as often as 
they result in good decisions, and that is not a very fine 
alternative either. So we've always, to be practical and to be 
reasonable in our patent system, included some words, words 
like obviousness, right, that we live with in Section 103 that 
requires some interpretation. I don't think of that as a 
problem with the patent system. I think of it as a strength of 
our patent system.
 Chair Tillis. I wanted to add, as somebody who works on the 
corporate side of patent issues and you see multiple sides of 
the retail industry, I am sure, can you help the Subcommittee 
put the retail industry patent issues in a larger framework?
 And then, Mr. Lemon, you can raise your card.
 Mr. Kappos. Yes, sure, happy to try to do that. So look, 
first of all, Chairman Tillis, I would say I am a big fan, like 
probably most others in this room, of the retail industry. When 
I was leading the patent office, I took many steps in order to 
help the retail industry, including in our implementation of 
the America Invents Act. And it is a great industry. We all 
want retailers to succeed.
 The issue and the perspective in my mind--and I believe 
that Mr. Lemon before mentioned some of the priorities of the 
NRF. I took a look at them also. As an example, the NRF's 
website lists top priorities, including tax provisions, trade 
strategy, tariffs, swipe fees, and organized retail crime. It 
doesn't mention nuisance patent litigation as a top priority. 
It doesn't even mention anything about patents as a top 
priority. In fact, it doesn't mention patent litigation at all 
as any priority. So I am sure there are some nuisance suits, 
but they are not mentioned as a priority at any level.
 So looking at that, I went and took a look then at the SEC 
filings, the 10-Ks, of the top 20 and the bottom 10 percent of 
the retail industry. And the 10-Ks, of course, are public 
documents that require all material issues to be disclosed. 
There are dozens of them that are in these 10-Ks. I couldn't 
find any of them, any of these companies that list nuisance 
patent litigation as a material risk factor. Slip-and-fall 
incidents, all these other ones that are mentioned here, retail 
fraud, et cetera, mentioned nothing about nuisance patent 
litigation. In fact, only a very few of them mention patent 
disputes at all, some of them on the offensive side, companies 
that are trying to assert their patents.
 So I come away from that feeling like, objectively, if you 
put this all in perspective, right, the retail companies 
themselves, the large ones and the small ones, are not listing 
nuisance patent litigation or any patent litigation as a major 
threat or a material issue for their business. So sure, we all 
would like to see less nuisance litigation of all kinds, slip-
and-fall suits, employment suits, et cetera, but it just does 
not show up on an objective basis, just looking at the 10-Ks 
and the statements made in websites as a material issue.
 Chair Tillis. Mr. Lemon, I am happy to have you respond, 
but I also want to make sure that you know that I have been 
pushing on third-party litigation funding, and at a minimum, I 
mean, this has become an industry that is highly disruptive. 
Sovereign wealth funds are investing in the U.S., and $2 
billion, I don't know if you follow Camp Lejeune toxins alone, 
$2 billion in third-party litigation funding. All I am asking 
for is that they win, they at least pay ordinary income like 
the victims have to.
 But if you got ideas on other things that I can do to bring 
these folks to the table, that there is a need for some of this 
litigation, but now it has just become another investment 
option for people who couldn't care about the victims. So know 
that we are on the same page there, but you can go back to Mr. 
Kappos' comments if you wish.
 Mr. Lemon. Well, I appreciate that we are on the same page 
on that. You know, I think retailers do care about patent 
issues. I mean, that is why I am here. I am here at the behest 
of my members. So retailers, many are large, complicated 
organizations that have lots of issues that they care about, 
and patents is one of them.
 You know, I think part of what the breakdown is in where we 
are coming at this issue, we all agree--and I was happy to hear 
the other witnesses while you were both absent. They recognized 
that they don't want low-quality nuisance patents either. So 
the goal is not to increase low-quality nuisance patents or 
nuisance lawsuits.
 From the retailer perspective, on the practical impact 
side, we look at the language of the bill. And I will tell you 
that I have not spoken to a single company in any of the 
sectors represented by UFPR, which is the majority of the U.S. 
economy, that agrees with the interpretation that this will 
keep business method patents out. We expect the language of the 
bill to allow business method patents back in, and these are 
the exact ones that we get sued on.
 Now, the bill does provide specific exclusion for rote 
language, but what happens when you craft it in a way that 
doesn't use rote language and instead just applies technical 
jargon around the process they are describing, the non-
inventive process, and they put technical language around it? 
That is what Alice said. You cannot put technical jargon around 
an abstract idea and make it patentable, patent eligible.
 Now, there has been a lot of discussion today also about 
the other Sections of the Patent Act, saying that they will do 
the heavy lifting to prevent things from becoming patentable 
just because they are ineligible. What I am saying is that 
wasn't the case before America Invents Act and Alice. Those 
Sections were not doing the heavy lifting necessary to keep 
business method patents out, so our members were being sued on 
an innumerable number of these patents. And the other Sections 
of the Patent Act did not do the work to keep them from getting 
patentable.
 So however you want to look at the entire act as needing 
some sort of reform, reforming just this piece and hoping that 
the other Sections somehow magically start to work better than 
they have worked in the past is not, on the practical side, 
going to be a good look for most of the economy of the U.S.
 And the last piece that I will say--thank you for giving me 
the time--is on the competing-with-China piece. From our 
perspective, PERA will not move us forward to competing with 
China the way that we are hoping because, one, when we relax 
standards for eligibility, which is what this bill would do, we 
are relaxing those standards for Chinese companies too. They 
participate. In fact, most of the patents granted by the patent 
office are to foreign entities. So we will be handing the keys 
to foreign Chinese companies to get lower-quality patents that 
they can come and sue our members. And so we will be sending 
money to Chinese companies who will be getting these patents 
that we are hoping Americans will start to innovate more, but 
there is nothing to prevent Chinese companies from coming and 
taking advantage of that.
 Chair Tillis. Mr. Cohen, do you have any comments since 
China was invoked?
 Mr. Cohen. China is invoked, and I always wake up. I think 
the logic of Mr. Lemon's position is that we shouldn't have 
patents at all because that way there won't be anything for 
Chinese to assert or others to assert. At least that is what it 
could easily be reduced to. We have to provide incentives for 
innovation in order to compete not only with China but with 
other countries throughout the world. And the reality is that 
other countries manage this issue without the same kind of 
disruptions and fear that have been invoked already. Europe has 
a different test, but it hasn't encountered the same problems. 
And the Chinese test is really pretty straightforward and 
simple in terms of a technical solution to a technical problem 
with a technical effect and that the issues of elemental 
processes and laws of nature are somehow integrated into that 
decision. And that is it. So it is not really an area of active 
debate for litigation.
 China and the U.S. is not a major litigant. I don't think 
we have seen the huge amount of litigation that some have 
feared, although China has been increasing its patent 
portfolio. And I think the proper counter to that is that we 
need to increase our patent portfolio in competitive 
technologies.
 Chair Tillis. Okay. And I am going to go ahead and so we 
can move to the next panel. But Mr. Lemon, have you reviewed 
the 2025 version of the PERA draft where I think--if you have, 
what I would prefer to do is instead of extending this so we 
can get to the next panel, we have added some language that I 
think addresses some of your concerns. But if you have and you 
still have concerns, this is an iterative process. I have made 
it very clear that I intend to get something done, and I 
believe that we are on a path to getting to a markup. I want to 
sincerely address the concerns of everyone who worry about 
passage of this bill. But I think on the whole, it is balanced 
and needed, and I am going to work hard to get it done.
 But I want every single one of you, regardless of where you 
are on the issue, to make sure you are talking with our office 
and we are doing our very best to be accessible and address 
your concerns.
 Thank you all. We are going to transition to the next 
panel.
 Welcome to all the witnesses.
 Mr. Blaylock, I know that you know about my debate format, 
and I know you were taking copious notes during the opening 
statements in the entirety of it. And Ms. Peschin, I saw you 
also back there taking notes, so I am looking forward to this 
panel getting started.
 Let me introduce Richard Blaylock. Mr. Blaylock serves as 
partner at Pillsbury, Winthrop, Shaw & Pittman LLP. Mr. 
Blaylock practices corporate and IP law for emerging and 
established life sciences companies in connection with 
financing, merger and acquisitions, licensing, collaboration, 
and partnering arrangements in IP counseling, as well as 
patent, license, trademark trade circuits and unfair 
competition disputes.
 Mr. Caltrider, did I get that name right?
 Mr. Caltrider. Yes.
 Chair Tillis. Thank you.
 Mr. Caltrider serves as the chief IP counsel at Dana-Farber 
Cancer Institute. Mr. Caltrider advises on the complexities of 
a global patent landscape, including U.S. and foreign 
procurement litigation and licensing matters. Prior to joining 
Dana-Farber, he served as vice president and general patent 
counsel for Eli Lilly and Company before retiring after 34 
years of service.
 Ms. Peschin, did I get your name right?
 Ms. Peschin. Yes.
 Chair Tillis. Serves as the president and CEO for the 
Alliance for Aging Research. Since 2012, Ms. Peschin has led 
the Alliance team in efforts to substantially increase Federal 
investment in Alzheimer's disease and aging research to develop 
Talk NERDY, a research engagement network for more than 200 
older patients, family givers, and researchers to advocate for 
equitable Medicaid, Medicare affordability and access. I love 
the Talk NERDY initiative, by the way.
 And let's see, Mr. Salsberg serves as vice president and 
global head of IP affairs at Novartis. A seasoned attorney with 
over 25 years of experience, Mr. Salsberg has testified before 
Committees of both chambers in Congress, has appeared before 
the World Intellectual Property Organization, or WIPO, and the 
World Health Organization, and the United Nations. He currently 
also serves as the president of the Federal Circuit Bar 
Association.
 Thank you all for being here.
 Mr. Blaylock, we will start with you.

 STATEMENT OF RICHARD BLAYLOCK, PARTNER, PILLSBURY, 
 WINTHROP, SHAW AND PITTMAN LLP, SAN DIEGO, CA

 Mr. Blaylock. Thank you, Chair Tillis, Ranking Member 
Schiff, and other Members of the Subcommittee. Thank you for 
the opportunity to address the topic of patent subject matter 
eligibility today.
 I will focus my remarks on the consequences of the proposed 
Patent Eligibility Restoration Act, or PERA, for the life 
sciences.
 The U.S. is and has been at the forefront of a revolution 
in personalized medicine. This has been made possible due to 
the sequencing of the human genome, the drastically increased 
affordability of genetic sequencing technology, and most 
importantly, the robust and ongoing exploration of the human 
genome. Researchers across the U.S. and indeed around the world 
have collaborated to identify variants within the genome that 
correlate with certain disease States, increased lifetime risk 
of disease, and suitability for certain drug therapies. These 
variants, or biomarkers, are clinically measurable facts about 
a patient that can inform both a patient and the patient's 
doctor about health and treatment. New biomarkers are being 
discerned on a daily basis, and the current law enables this 
important work.
 Regrettably, PERA would slam the door shut on access to new 
biomarkers. PERA would allow the privatization of medical 
knowledge through the patenting of biomarkers and preemption of 
all methods of their detection, including any research or 
clinical use of them.
 Under current law, as articulated in a series of 9-to-0 
Supreme Court decisions--even on the Supreme Court, patent law 
is bipartisan--correlations between biomarkers and clinically 
important patent information, natural laws in the parlance of 
Supreme Court jurisprudence is not eligible for patenting. 
Thus, the discovery of basic facts about human biology are not 
patentable, nor can they be made patentable by simply combining 
those facts with existing conventional technology for their 
detection.
 This state of the law is a consequence of the Supreme Court 
grappling over the decades with very real concerns about the 
negative consequences of allowing the preemption of basic 
natural laws through patenting. This state of affairs allows 
the entire research and clinical community to make use of this 
knowledge in advancing medicine and individual patient care 
because no one can use a patent to bar or impair access to this 
information.
 It is also critical to recognize that the current law does 
not prevent the patenting of new and innovative technologies 
for detecting biomarkers. You heard former Director Iancu 
announce that patents on diagnostic technologies in the U.S. 
are not allowed. That is just categorically false. Many 
companies continue to advance the field through the development 
of new diagnostic platforms that improve the range and 
efficiency of techniques for diagnostic testing in its myriad 
forms, and they are getting patents on these.
 Senator Tillis, you mentioned that Director Squires had 
recently signed a new patent related to diagnostics. Perfectly 
fine. That is a patent that is directed to novel antibodies. 
There is nothing about the current law that prevents the 
patenting of new antibodies that may be useful in diagnostics, 
and so the current law does not impair the advancement of the 
diagnostic field.
 And additionally, many new point-of-care diagnostic testing 
platforms are being developed and patented and brought to 
market, and these point-of-care platforms are advancing patient 
care by allowing physicians to receive answers to lab tests in 
minutes within the clinic without needing to wait days by 
sending samples to outside labs.
 Current law retains the valuable patent incentives to 
develop new and better ways to conduct laboratory tests and new 
tools for doing so. It simply does not allow any one person to 
claim ownership of basic medical knowledge in the form of the 
results of those tests.
 PERA would change that to the detriment of patients, as 
well as a functioning diagnostics industry. There would be a 
proliferation of patents covering the many biomarkers of 
interest necessary to standard-of-care genetic testing for many 
conditions. Any of scores of new patentees, whether in the U.S. 
or in China, could stand in the way of a clinician's effort to 
conduct a comprehensive analysis of a patient's genetic 
information. Permission would need to be secured from all of 
them, none of whom under U.S. law would be obliged to grant 
such permission. PERA would return the U.S. to a time when 
patients had to fight for affordable access to most 
scientifically up-to-date testing.
 Also, I want to note that PERA would not bring clarity, 
unfortunately, to the law, and I have mentioned other issues in 
my written testimony, but I will simply note that PERA 
identifies a closed set of exclusions to patent subject matter 
eligibility. But sadly, these are just Potemkin exclusions as 
they relate to human genes and natural materials because these 
exclusions are subject to additional conditions in the 
statutory language which hollow out the exclusions to the point 
that there is little or nothing they actually exclude. You 
could omit those exclusions from PERA, and PERA would have the 
exact same effect. They are window dressing, sadly, but nothing 
more.
 I see my time is up, so I wish to say thank you for the 
opportunity to speak with you today on this very important 
topic. I look forward to the opportunity to rebut some of the 
other comments I heard earlier today. Thank you.
 [The prepared statement of Mr. Blaylock appears as a 
submission for the record.]
 Chair Tillis. And we will certainly submit your formal 
statement to the record.
 I did want to point out, I talked about Mr. Squires picking 
two patents to sign. I think that was to send a signal that 
those particular ones are now eligible. But I get the points 
that you made in your argument, but I think that is the point 
he was trying to make by the ceremonial signing.
 Mr. Caltrider.

 STATEMENT OF STEVEN CALTRIDER, CHIEF IP COUNSEL, 
 DANA-FARBER CANCER INSTITUTE, BOSTON, MA

 Mr. Caltrider. Thank you, Chairman Tillis, Ranking Member 
Schiff, and Members of the Committee for the opportunity to 
present this testimony.
 I currently serve as vice president and chief intellectual 
property counsel at the Dana-Farber Cancer Institute. I 
provided written testimony on patent eligibility to this 
Subcommittee in June 2019.
 Unfortunately, little progress has been made on the 
eligibility crisis. Please make no mistake, this is a crisis. 
The fact that innovators are adapting into the current legal 
framework and managing as best they can does not mean the 
crisis is solved.
 Opposition to the current law of eligibility is often 
justified as an issue of patient access. I wholeheartedly agree 
that patient access is critical. It is why innovators and 
caregivers at Dana-Farber do what we do. Our mission is to help 
patients with innovative therapies and scientific discoveries. 
The ultimate barrier to patient access, however, is a medicine 
or a diagnostic never being discovered, developed, or 
commercialized. Patients who never receive the diagnostic 
testing that enables earlier detection or the treatment that 
could have saved their life are unquestionably denied access.
 Denying patient access to discoveries never developed and 
commercialized due to poor IP policy is the real travesty. 
Lives are impacted and likely lost. That makes it all the more 
important to act urgently. I noted in my 2019 testimony, 
patients are waiting. They are still waiting.
 Dana-Farber does not undertake the development necessary to 
commercialize its research. For innovation to reach patients 
broadly, we work with commercial partners who make the 
substantial investment to secure the necessary regulatory 
approvals. The uncertainty of strong patent protection puts 
this investment in these critical partnerships with the private 
sector at risk.
 Unfortunately, the crisis now threatens innovative 
treatment options. The Regenexbio v. Sarepta Therapeutics case 
was heard yesterday by the Federal Circuit. The claims at issue 
in Sarepta are directed to engineer host cells useful for gene 
therapy. This isn't the forum to litigate the merits of the 
case under current law, but this is the forum to step back and 
ask the policy questions. Should there be any doubt that the 
subject matter in engineered cell combining known portions of 
nucleic acid useful to deliver a gene to patients to provide 
hope for a cure is not patent eligible? Without a question, it 
should be.
 These gene-based treatment modalities are also not the only 
treatments at risk. Claims to manmade peptides called degrons 
have been rejected. Claims directed to antisense 
oligonucleotides have been rejected. Claims directed to RNA-
based therapies have been rejected.
 While the legal landscape for treatment-related patents is 
not yet as dire as the medical diagnostics, defending against 
patent eligibility challenges creates a strong headwind against 
innovation and remains only one adverse court decision away 
from being catastrophic for patients.
 But what about patient access? I am certain that patents 
and PERA in particular are not a barrier to patient access. The 
current standard of care and testing of genes linked to 
hereditary cancers will not change or be impacted by PERA. 
Plainly stated, you cannot patent what is already known and 
standard of care. As I noted, opponents of PERA argue that the 
current law prevents patents of unprecedented scope and ensures 
that the fundamental building blocks cannot be monopolized. 
Respectfully, the argument is misplaced. A patent holder can no 
more control all preclinical and clinical research on a human 
gene after this bill passes than they could today. In my 
opinion, what PERA's opponents are really against is the loss 
of an opportunity for a quick kill in litigation.
 The cost required to litigate a patent is a real issue, but 
furthering the eligibility crisis because it is maybe faster to 
kill certain patents that lack merit is throwing the baby out 
with the bathwater. It is obviously not good IP policy to 
undermine lifechanging innovation so that so-called low-quality 
patents are more easily invalidated.
 The legislative history of the Patent Act makes clear that 
Congress intended to broadly cast patent eligibility. This was 
for good reason. Today's inventions were unimaginable. A more 
restrictive eligibility criteria risks the very problem that we 
confront today through judicial fiat. Entire promising fields 
of research are threatened by misguided eligibility standards. 
Congress was correct that eligibility should be broadly cast.
 Remarkably, the Federal Circuit judges in Athena 
Diagnostics noted that Supreme Court ignored or disregarded 
Congress' wishes. PERA corrects this disregard by defining 
eligibility broadly and letting the substantive Sections of the 
patent statute 102, 103, and 112 do the heavy work of sorting 
meritorious inventions from unpatentable subject matter.
 In closing, I commend you and your staff for your continued 
efforts on this legislation, and I welcome the opportunity to 
assist in any way I can. Thank you.
 [The prepared statement of Mr. Caltrider appears as a 
submission for the record.]
 Chair Tillis. Thank you. Ms. Peschin.

STATEMENT OF SUE PESCHIN, PRESIDENT AND CEO, ALLIANCE FOR AGING 
 RESEARCH, WASHINGTON, DC

 Ms. Peschin. Chairman Tillis, Ranking Member Schiff, and 
Members of the Subcommittee, thank you for the opportunity to 
testify today. My name is Sue Peschin, and I serve as president 
and CEO of the Alliance for Aging Research.
 The mission of the Alliance is simple. We are dedicated to 
changing the narrative to achieve healthy aging and fair access 
to care. Personally, I am a family caregiver to my mom, who is 
84 and lives with kidney disease, severe arthritis, and 
dementia. Today's hearing is not an abstract policy debate for 
older adult patients and family caregivers like me. This is 
about lives, choices, and hope.
 All of us rely on medical breakthroughs that begin with 
discovery, but for over a decade, our patent system has struck 
down thousands of patents and failed to protect some of the 
most transformative innovations in diagnostics not because they 
weren't new or useful but because of confusing eligibility 
standards that made the system inconsistent and chaotic.
 The root cause of this major shift was a series of Supreme 
Court cases. Several witnesses here today are experts in the 
details of these. I am not one of them. But I do bring five 
observations to share as a patient advocate that I hope that 
you will consider.
 The first is Federal Circuit judges themselves have asked 
Congress to resolve the confusion resulting from the Supreme 
Court's decisions. In the case of Ariosa v. Sequenom, Judge 
Linn stated, ``But for the sweeping language in the Supreme 
Court's Mayo opinion, I see no reason in policy or statute why 
this breakthrough invention should be deemed patent ineligible. 
In my view, the breadth of the second step of the Mayo test is 
such that it is difficult to imagine any diagnostic claim that 
could survive. If the law is to be changed, and I believe it 
should be, that change must come from Congress.'' So it is up 
to you to fix this.
 Second, the 2012 Mayo decision and others that followed 
made it nearly impossible to patent diagnostic tests that rely 
on biological markers, the very tests that tell us who has 
cancer, who will benefit from a therapy, or who might suffer an 
adverse reaction. These aren't just ideas on the blackboard. 
These are real tools developed by researchers, tested in 
trials, and used by families to make decisions that affect 
their future.
 Others here might argue that new biomarkers could be 
detected on already existing assays. What does that matter? 
Without patent protection, many of these tests are never 
developed, or they sit on a shelf because no one will fund 
them.
 Third, when innovators can't get patents, they often 
withhold discoveries as trade secrets, especially in 
diagnostics. That hurts scientific transparency, and it slows 
progress. During the patent application process, companies 
publicly disclose their invention, which allows for future 
innovation. Trade secrets stay secret.
 Fourth, there is no doubt that there have been bad actors, 
but we can't fix litigation abuse by breaking innovation 
incentives. Researchers at numerous top American universities 
have left behind novel diagnostics for lupus, Alzheimer's, 
major depressive disorders, cancers, including metastatic 
cancers, schizophrenia, and rare pediatric disorders after the 
USPTO rejected or weakened their patents because of the 
eligibility rules in Mayo, and that is heartbreaking.
 Fifth and last, I am personally encouraged by the fact that 
the former directors of the U.S. Patent and Trademark Offices, 
under both Presidents Trump and Obama, are testifying in favor 
of this bill and that the bill has bipartisan support in both 
chambers of Congress and among many former Federal Circuit 
judges. There is shared agreement that something is wrong and 
shared commitment to fix it. That doesn't happen often these 
days, and patients don't have time to wait.
 The Alliance for Aging Research is honored to strongly 
support the Patient Eligibility Restoration Act of 2025, or 
PERA. PERA would restore the balance. It doesn't let companies 
patent nature. It allows them to patent inventions that apply 
human insight to nature, to turn discoveries into action, into 
treatments, and into better outcomes for patients. When patent 
law works, patients benefit. We get earlier diagnoses, more 
effective treatments, and more personalized care. When it 
doesn't, we lose time, we lose tools, and we lose lives.
 Thank you, and I look forward to your questions.
 [The prepared statement of Ms. Peschin appears as a 
submission for the record.]
 Chair Tillis. Thank you. Mr. Salsberg.

STATEMENT OF COREY SALSBERG, VICE PRESIDENT, GLOBAL HEAD OF IP 
 AFFAIRS, NOVARTIS, EAST HANOVER, NJ

 Mr. Salsberg. Thank you. Chairman Tillis, Ranking Member 
Schiff, and Members of the Subcommittee, on behalf of Novartis, 
a leading innovative medicines company, and a pioneer in cell 
and gene therapies and other advanced technologies, thank you 
very much for the opportunity to testify today in support of 
PERA, a bill that restores much needed clarity and strength to 
the U.S. patent system.
 In the 6-years since I last testified before this 
Subcommittee on this issue, patent eligibility law in America 
has gone from bad to worse. While we worried then about the 
law's lack of clarity and the many useful inventions that had 
been shut out of the patent system on account of it, our main 
concern was for the future. The Supreme Court, we feared, had 
created a judicial snowball, a test so ill-defined, it would 
lead the lower courts to continually expand the scope of what 
cannot be patented, well beyond what the Supreme Court intended 
in Mayo, Myriad, and Alice, and into the core fields that were 
defining the future of medicine.
 Our predictions, unfortunately, were only too accurate. 
Just yesterday, the Federal Circuit heard oral argument in a 
case with potentially dire consequences for biotechnology. The 
case, the one that Mr. Caltrider just mentioned, Regenexbio v. 
Sarepta, concerns patents on genetically engineered host cells 
that produce the type of viral vectors in gene therapy to 
deliver missing genes to patients, treating and potentially 
curing a range of diseases. The engineered cells in the case 
are created in a laboratory and include recombinant DNA 
sequences made up of genes spliced together from at least two 
completely different species of organism. Even the accused 
infringer in the case agreed that cells like this do not occur 
in nature, and yet the district court found them to be patent-
ineligible products of nature because they are built from 
components of nature.
 The decision is as legally wrong as it is illogical. The 
compositions of matter have been statutorily patent eligible 
since 1793. In 1980, in a landmark decision called Chakrabarty, 
the Supreme Court held that organisms produced by genetic 
engineering in precisely this way are non-natural compositions 
of matter that plainly qualify as patentable subject matter. It 
later reaffirmed this precedent in Myriad when it distinguished 
the isolated human genes it found ineligible there from 
applications and modifications of genes which it held to be 
eligible. And yet the District Court in Regenexbio still 
decided what it did.
 The implications should worry everyone. Chakrabarty's 
confirmation half a century ago that genetically engineered 
organisms are patent eligible is widely credited with having 
spawned the U.S. biotech industry, giving rise to everything 
from gene sequencing tools to monoclonal antibodies to today's 
gene therapies. If Regenexbio stands, it threatens not only the 
future of those fields, but countless inventions in almost 
every field because, as the Supreme Court has reminded us many 
times, all inventions at some level embody, use, rest upon, or 
apply laws or elements of nature.
 Even if the Federal Circuit reverses the decision, it 
cannot reverse the increased uncertainty the case has 
unleashed. If one court can so easily brush aside half a 
century of precedent, innovators know that it is only a matter 
of time before another does the same with perhaps a different 
outcome next time on appeal.
 That is the stark reality of a body of law that the Federal 
Circuit itself has called panel dependent when it has said it 
is at a loss as to how to consistently apply. It is also what 
has already happened with patents on biotechnological methods. 
Mayo's bar on certain diagnostic methods now bars patents on 
basically all diagnostics. Even method-of-treatment inventions, 
which the Supreme Court in Mayo said are eligible, have since 
been questioned. And to make things worse, eligibility today 
often comes down not to what invention a patent covers but to 
what words are used. Methods of detecting, optimizing, and 
determining are out, but methods of preparing, operating, or 
regulating for basically the same purpose just might be 
eligible.
 Patent eligibility law should not be this complicated. It 
is simply a matter of deciding what types of innovations the 
U.S. wants to promote and what types it does not. The 
Constitution entrusts those decisions exclusively to Congress, 
and with the Supreme Court having now denied at least 64 cert 
petitions seeking further clarity since Mayo, it is clear 
things will not improve unless Congress acts.
 Innovators in gene-based medicine badly need that 
intervention. As a pioneer in the field, we are counting on the 
U.S. and its patent system to support our efforts to develop 
the next wave of these technologies here. Earlier this year, in 
fact, we announced plans to invest an additional $23 billion to 
expand and enhance our longstanding U.S. R&D and manufacturing 
infrastructure. With commitments of this scope, we need to know 
that the patents that enable us to start our work at the 
frontiers of medicine will still be eligible if and when we 
succeed in converting the bold leads they encompass into 
tomorrow's cures.
 PERA provides that reassurance. By defining what is 
eligible and what is not, PERA reigns in the snowball that 
eligibility law has become and restores the predictability that 
cases like Regenexbio take away. While the bill still sets 
America's patent laws behind China's, Europe's, and Japan's, 
all of which allow patents even on isolated human genes without 
any of the ill effects that critics claim would happen here, by 
codifying Myriad, PERA at least makes clear to American 
innovators that if they modify or apply genes, the foundations 
of biotechnology, their efforts will not go unrewarded.
 Thanks again for the opportunity to testify. I look forward 
to your questions.
 [The prepared statement of Mr. Salsberg appears as a 
submission for the record.]
 Chair Tillis. Thank you, Mr. Salsberg.
 I am going to turn to Senator Hirono. She was a bit 
surprised that I asked her if she wanted to go first, but the 
reason I want to give her every opportunity to go first is she 
is one of the most consistent attendees in these hearings in 
the years that I have been here, and I want it to be a positive 
experience for her.
 [Laughter.]
 So Senator Hirono.
 Senator Hirono. You know, as a psychology major, I know 
what positive reinforcement involves. It is like Pavlov's dog. 
You know, you say, here, you get to go first, and the behavior 
continues, so it is very smart of you. And then I thank my 
colleague for letting me go first. But I do thank you, Mr. 
Chairman, and our Ranking Member for this hearing, which might 
teach us a thing or two. So this is like a normal hearing. It 
is nice. And, of course, I want to thank you and Senator Coons 
for being a leader on making the kinds of appropriate changes 
to eligibility reform.
 I do acknowledge that the Supreme Court's decision in Mayo 
and Alice that took place over 10 years ago created a lot of 
confusion and upended precedent, and, as I said, introduced 
great uncertainty into our patent system. And appealing to the 
Supreme Court to remedy this situation have fallen on deaf ears 
to the court that actually engaged in writing legislation when 
they did their decisions that created this chaos in my opinion.
 So here we are with a bill that would create some level of 
certainty into a system that I think is really important, 
especially in the medical research area. And I do acknowledge 
how important innovations in diagnostics are critical to 
millions of people in our country.
 So this is a bill that has gone through some iterations. I 
think the biggest change in this year's bill, I think, is that 
we make it clear that you can't patent an individual gene, and 
that is to respond to some of the concerns that were raised in 
earlier versions of this bill. But, you know, I am certainly 
open to other discussions and changes about potential research 
relating to genes.
 So as we go forward, I think not only is it important that 
we provide this level of clarity that the Supreme Court has not 
seen fit to address in over 10 years, but I think we should be 
open to any further amendments that will make the system work a 
lot better and, at the same time, create an environment where 
we our country will continue to be a leader in medical 
research.
 Basically, this regime--I call it a regime--their cuts to 
NIH funding really raises concerns about our continuing 
leadership in medical research. And certainly, this kinds of 
confusion in our patent system do not help, and that is why we 
can do something about it with this legislation.
 For Mr. Caltrider, there were concerns raised with the, as 
I mentioned, the previous version of this legislation relating 
to the eligibility for human genes to be patented, and whether 
those genes could have actually been patented was a different 
question. But this version of PERA specifically provides that 
human genes isolated as such should not be eligible. So in your 
view, does this limitation of patent eligibility strike the 
right balance between not allowing the patenting of human genes 
while still in [off mic].
 Mr. Caltrider. Thank you for the question. The short answer 
is, yes, it does. The patentability of genes is an interesting 
question because I think it actually is--you can deal with it 
as an eligibility issue, which the bill does and says they are 
not eligible. They are also not patentable at this point in the 
sense the genome has been sequenced, and the prospect of 
getting a patent on a gene at this point really is resolved. 
Whether it is in eligibility or whether it is in 102, it is not 
available any longer. So it is an issue that is, in my view, 
resolved, and it strikes the right balance.
 Senator Hirono.
 [Off mic.]
 Mr. Caltrider. No, that is not what I am saying. I am a 
little bit neutral on the language, because it, but if it makes 
people who oppose the bill more comfortable to have that in the 
bill, I am fine with it being in the bill. I think you get the 
same result whether it is there or not, but if it helps advance 
the legislation, I agree with it.
 Senator Hirono.
 [Off mic.]
 Mr. Salsberg. We are fine with the limitation. We think it 
basically codifies Myriad's distinction between isolated genes 
and modifications and applications of genes, which enables us 
to do the work we need to do to invent tomorrow's cures.
 Senator Hirono.
 [Off mic.]
 Ms. Peschin. I agree.
 Senator Hirono.
 [Off mic.]
 Mr. Blaylock. Regrettably, I would delete the entire draft 
because I genuinely believe that the current law is superior to 
[off mic]. That said, if over time, if PERA is advancing and, 
you know, if your office or Senator Tillis' office is open to 
dialog on the language, I am willing to address it.
 This is not what I would call my improvement, but since 
Senator Hirono was just asking about genes, let me speak to 
this one point. The exclusion here is only for human genes. And 
while it is true the human genome is, you know, has been 
sequenced, human health is also related to the genomes of the 
myriad pathogens that we encounter. All of those, including for 
SARS-Coronavirus-2, its genes would also have been patentable. 
SARS-Coronavirus-3, which I hope we don't encounter, but if it 
does come, its genes, you know, could be patented, and that 
could control, you know, the response to a next pandemic.
 Similarly, as much as it says an unmodified human gene as 
it exists in the human body is excluded, the next page says, 
oh, by the way, don't consider it unmodified, which means the 
exclusion has no effect. If that human gene is purified, 
enriched, otherwise altered by human activity, or even if it 
isn't, even if it is exactly unmodified as it exists in the 
body, as long as you use it in some useful practice, well, that 
is not an exclusion at all. I would defy someone to come up 
with anything other than claiming that my walking around with 
the gene functioning in my body, you know, is an infringement. 
I cannot think of a way to write a claim that would be 
excluded, you know, with this language.
 Senator Coons. Mr. Caltrider, if I might just ask you, Mr. 
Blaylock is essentially saying PERA imposed no limits 
whatsoever on the patenting of genes. Would you agree with that 
critique? And how would you explain the difference between his 
characterization and yours in your support of this bill?
 Mr. Caltrider. Well, let me go to the question on genes of 
pathogens because I think it is a good question to ask. In my 
view, I don't--a gene to a pathogen may be strictly eligible, 
but I don't see how it is patentable. Even under Section 101, a 
gene must have a substantial and practical use. And In re 
Fisher disregarded many of the uses in research that you 
would--or found that many of the uses in research that might 
be--a pathogen's gene might be useful for do not give it 
utility, so I don't see how it is useful to begin with.
 In terms of human genes, I think you have to read that 
clause--really, it should be drafted narrowly. Who would 
imagine where we would be with gene therapy today, cellular 
therapy today? If you aren't very, very careful on how that 
language is proposed--in fact, you didn't ask me, but what I 
would change is probably delete those exceptions as being 
unnecessary because I think that you run the risk that we don't 
know where the science is going to go. And do you, will you 
preempt the future by virtue of having language that today 
looks reasonable and something workable and something that many 
people in the life sciences can compromise to, but in the 
future, is it going to have unintended consequences because we 
simply do not know how science is going to develop?
 Senator Coons. I understand your concerns. A core concern 
of ours is getting this passed, if you will forgive my 
practicality.
 Ms. Peschin, if you had one change you would suggest or one 
issue you wanted to raise before my time is up, I would welcome 
it.
 Ms. Peschin. Thank you. I support keeping this in. And the 
reason why is because Mr. Blaylock continues to say, both 
verbally and in his materials, it doesn't include this, but it 
includes it. And, again, it is sort of mirroring the confusion 
that has been created by the Supreme Court cases from my 
perspective as a patient advocate. And I think it does create 
kind of public confusion around it. So I think putting it in 
definitively that it does not do this is important.
 Senator Coons. In conversations with colleagues in the last 
Congress, it was an issue. And part of the point of including 
this language was to resolve and clarify this concern. And to 
have patient advocates, researchers, folks who represent world-
class institutions saying this matters and we can live with it 
helps a great deal.
 Thank you all for your testimony. Thank you, Senator 
Tillis.
 Chair Tillis. Senator Schiff.
 Senator Schiff. Thank you. And I apologize to make you 
repeat yourselves, but----
 Chair Tillis. No, it was great. A Republican has yet to ask 
questions.
 [Laughter.]
 Senator Schiff. Mr. Caltrider, what do you say to Americans 
who are worried that allowing companies to patent medical 
diagnostic tests would make those tests unaffordable, as we saw 
with BRCA1 and 2 in Myriad at $4,000 a test? And Mr. Blaylock, 
I would love to hear your contrary view, point/counterpoint if 
we could.
 Mr. Caltrider. Certainly, patient access is important, and 
price is important. And those issues are really different 
issues than patent eligibility. The BRCA patents were invalid. 
They were invalid under 112 and 102. If things have gone its 
natural course, the law would have developed even more under 
102 and 112 to yield the very same outcome on those patents.
 The issue is an eligibility question, which is a different 
question than patentability. That subject matter, in my 
opinion, should have been eligible, but the patent should have 
been struck down for other reasons because they were drafted 
too broadly. The definition of isolated made the patent read-on 
and lack novelty. The claims were invalid under 112 in 
overbreadth, and that is a real issue for patents, and the law 
needs to continue to evolve, and it has evolved. The Morris 
case is cited oftentimes as being a 101 case, but if you read 
it carefully, I think it is a 112 case. It is just the statute 
wasn't quite in place. The 1952 act came after Morris rather 
than before Morris to make it really, really quite clear.
 So from an eligibility perspective, I think it is eligible. 
It is a completely different question whether it is patentable. 
And then if it is patentable, then you want that innovation. 
You want new outcomes. You want new diagnostics. You want new 
treatment options for patients. And the pricing issue is a 
serious issue. Dana-Farber is very sensitive to that, but it is 
really a different issue.
 Senator Schiff. And do you share that opinion, Mr. 
Blaylock, that this is not a patent issue, it is a pricing 
issue?
 Mr. Blaylock. Well, I think the pricing issue sometimes 
follows the patent issue because the reason why the Myriad test 
was $4,000 a test was because of the patents. And I can tell 
you that I was counsel of record in the multi-district Myriad 
litigation that was going on, you know, in Salt Lake City, 
Utah, that Myriad owned or controlled about approximately 24 
patents with over 500 claims, and they were not all invalid. 
They continued to be valid at the time when Myriad 
unconditionally dropped its suit, but those patent claims were 
not invalid. Yes, there were three or four, maybe five patent 
claims to specific genes that were invalidated in the Supreme 
Court case, but that had no commercial effect. They still had 
an enormous patent war chest, which they were asserting against 
the entire genetic testing industry, and hence that litigation, 
which was ongoing after the Myriad case.
 In terms of what is important to understand is we are not 
arguing about patents of genes. We are talking about patents of 
the observed variations in human genes. My genome and your 
genome are not identical. Some of those differences have 
clinical relevance. They could indicate whether one of us has a 
greater likelihood of contracting a disease in the future or be 
a better responder to medicine.
 Those kinds of observations are being made today on an 
ongoing basis. It requires aggregation of large amounts of 
data. And the, this law would allow all of those new 
observations to be individually patented, where the only thing 
that is a subject of patent is the discovery of that biological 
information.
 Now, by contrast, if one invents a new technique for 
getting a gene, even a known gene, into the body, so you have a 
new vehicle for doing this, if you have a better way of doing 
genetic testing, if you are Illumina and you make better 
machines, if you are PacBio and you make better machines, you 
can get those patented.
 But what we are talking about, the problem with PERA, is 
that it specifically allows this new information, which is 
continuing to evolve, which is understanding the details of 
variation in the human genome, which is not all known, to be 
patented and controlled in an individual way, and that will 
impair access, either from pricing or simply injunction.
 Senator Schiff. And Ms. Peschin and Mr. Salsberg, would you 
like to share your thoughts on it as well?
 Mr. Salsberg. Yes, maybe I will make two points. One is we 
strongly disagree with that interpretation of what PERA does. 
PERA, at least as we read it, it codifies Myriad. It codifies 
the distinction between isolated human genes, which is the only 
thing that that case actually held as not patent eligible, and 
applications and modifications of genes. In Myriad itself, the 
court said that cDNA, for example, is patent eligible. It found 
that methods of analyzing genes would be patent eligible. We 
need to distinguish between the gene itself, which PERA does, 
and applications and modifications, which are really the 
foundations of things like cell therapy, gene therapy, and 
other gene-based medicine.
 The other point I would make in response to a lot of these 
concerns is that--I really want to hit this point because it is 
really important to consider. China, Europe, and Japan have all 
allowed continuously patents not only on the types of 
applications and modifications of genes that we are talking 
about here and that we are concerned about as innovators, but 
even on isolated genes, sequences that are exactly the same as 
nature, and they have not led, including during the pandemic, 
to any of these concerns. In fact, the coronavirus was 
sequenced in China and Europe but just as quickly as it was 
here. So if they can figure it out, it seems to me that we 
ought to be able to figure it out here too without crippling 
our patent laws.
 Senator Schiff. Thank you. Ms. Peschin.
 Ms. Peschin. Thank you. So you said a lot, but I am going 
to just address a couple of things. One is I think it is 
misleading to say the price is because of patents, and in 
particular, I think, to patient advocacy community and really 
to consumers. You know, a lot of these diagnostics wouldn't 
exist without the patent, so the patent, in many ways, gives us 
something to complain about with regard to price. It really 
encourages investment in that type of research and being able 
to bring it to fruition.
 And I think it is really interesting, and in the arguments 
I have seen against this remedy, I really haven't seen anything 
about the concern for cost when you don't have the innovation 
at all, when you have family members that have conditions that 
have no diagnostics, of which the majority, you know, of 
diseases that are out there, especially in the rare space, 
really have no way of diagnosing. And that is something that we 
also should consider.
 The other thing I wanted to say with regard to the claim 
that folks are just sort of bringing these things to market, 
they are doing it by putting their inventions under trade 
secret, and trade secret doesn't become public, so folks are 
not able to mirror and mimic. And as part of the patent 
application process, that is made public so further innovations 
can occur. And I think all these different facets are important 
to remember when you think about, you know, what is being said.
 And then the last thing I guess I would say is, if you have 
a gene, a variant on a gene from a rare disease or something 
else, and you are able to use an existing assay to identify 
that, that should be a good thing. You know, there was a study 
that was done by the SMU professor David Taylor, and he looked 
at the negative impact on investment-making decisions. And in 
his study, he interviewed 475 venture capital and other private 
equity investors to study the impact of the Supreme Court 
cases. And 74 percent of them considered patent eligibility to 
be an important factor when their firms decide to invest in 
companies developing new technology. So if we continue to 
impede in this way, you know, we are limiting future 
innovations, and that worries me from the patient advocacy 
perspective.
 Senator Schiff. Thank you very much.
 Thank you, Chairman.
 Chair Tillis. Senator Schiff, I should have clarified by 
saying I haven't gone yet. When I said no Republican had asked 
a question, I let Senator Hirono go before me.
 Senator Schiff. I bet you figured that out.
 Chair Tillis. Yes. We have some other Members, I know, are 
interested. We are in interesting scheduling times right now.
 I want to go back and give you some context for--I have 
said this before, I am not a lawyer. I am a business guy, a 
management consultant. But I started my career in high tech as 
a product manager at Wang Laboratories in Boston. And that is 
where I understood where I was tasked with making the decision 
about whether or not this really smart propeller head engineer 
from MIT had a great idea that we were going to make an 
investment in, and intellectual property absolutely either 
expanded or reduced my buy box for investing, absolutely did.
 Now, Ms. Peschin, you wouldn't know this, but I was a 
caregiver to a grandmother who suffered from early onset 
Alzheimer's back in the 1990's, received training on it, and I 
have given training on caregiving. And from the lens of--this 
is also to give you all an idea of where I am thinking beyond 
just the subject matter expertise that you all bring into the 
room to the more practical issue.
 And I don't mean this to be political, Senator Schiff, but 
the Inflation Reduction Act had a policy in it that 
dramatically reduced funding--or it actually cut the prices 
of--basically whacked pharma. And there was an immediate 
measurable more than 50 percent reduction in small molecule 
research over the course of a year. In fact, it was so 
pronounced that the CEOs felt it was important to go on the 
shareholder calls and make it clear that they had to do that 
because they did not simply have the money to actually fund 
that research. Well, similarly, if you have--that is 
uncertainty. It is about, you know, the future flow of revenue 
to fund research.
 If you have similar uncertainty in this investment that you 
are about to make in a future cure, you've got all these other 
stressors and unknowns that are just going to continue to 
dramatically reduce the buy box for American innovation. Not to 
say that they won't be picked up in Europe for the reasons that 
Mr. Salsberg mentioned, and I am going to have Mr. Blaylock 
speak about that as well, but I am thinking through the lens 
of, number one, accelerating some of the most promising 
research that we can have in the biotech space, that the 
enormous societal, human, and fiscal implications are 
immeasurable, which is why I feel like this is one small step 
in that direction that expands the buy box, increases our 
innovation posture here, and I think has dramatic impact on 
lives, both fiscally, humanitarian, at every level.
 Mr. Blaylock, why hasn't Europe experienced some of the bad 
things that you think happen if we do this here?
 Mr. Blaylock. Well, first off, although I am a lawyer, I 
work with business folks all the time. I work with startups. I 
work with folks that are trying to develop new technologies in 
life sciences elsewhere, so I am keenly aligned with you with, 
you know, those concerns.
 People look to the U.S. much more than Europe for as the 
market that will determine whether they want to pursue, you 
know, any particular life science technology, and that is tied 
to pricing. And patents are just a small piece of the ability 
to get reimbursement for new medical technologies. So I think 
the differences between U.S. and Europe are driven by other 
factors, not so much by patent subject matter eligibility.
 But I think one thing that I would address here that I 
think is very, very important is the drivers for innovation, 
and it is this. People often talk about the cost of a new drug 
being $1 billion or sometimes people have upped it to $2 
billion. When I am talking about new genetic tests, this is 
information that comes out of genome sequencing, which you can 
do $1,000 a pop. It is not a billion-dollar investment by a 
company in order to make this information--and indeed, contra 
to the suggestion that it is all going to be trade secrets, 
honestly, the clinical acceptance of the kinds of information 
we are talking about that we think should not be part of what 
would be patented under PERA is necessary, and therefore, this 
information is not being held as a trade secret. It is being 
published. It is being generated today. This last 10 years has 
not stopped the flood of this information. My concern is PERA 
would staunch that flow of innovation and make it that much 
harder for people to access it.
 Chair Tillis. Does anyone have any comment on that? I don't 
know. I have kept you all up here.
 Mr. Salsberg. Just briefly, I would say that, you know, we 
are not interested in patenting genes from what we do, but what 
we are interested in is having clear patent eligibility laws 
that don't keep changing and expanding into new territory every 
year and every time we have a case like Regenexbio. And if we 
don't stop this, then we are now moving away from the Myriad-
type cases into the core of the technologies that we are trying 
to develop for tomorrow, which are clearly applications of 
this. So the courts definitely need guidance, separate and 
apart from the debate over whether isolated genes by themselves 
should be patentable.
 Chair Tillis. In some respect, if a business person is 
watching this, I mean, this is just about eligibility. It is 
not about an ultimate patent being granted. Isn't that a good 
thing to increase the pipeline? And doesn't it seem like there 
are guardrails beyond 101 that address most of the concerns 
that Mr. Blaylock had mentioned? That is a business guy asking 
kind of a legal question, so it is very dangerous.
 Mr. Salsberg. One more quick response, and Mr. Caltrider 
referenced this earlier. I mean, if you read the Supreme Court 
case law about how broad Section 101 was written from the 
beginning, it is precisely because science is unpredictable. 
And lawmakers early on from this country's birth did not want 
to set the limits of where research should go. And you are 
absolutely right. Eligibility is just the signal that this is 
where you should invest in general, and from there, the rest of 
the Patent Act will narrow down what is patentable and what is 
not.
 Chair Tillis. Mr. Caltrider or anybody else for closing 
comments? We are going to close out the hearing.
 Mr. Caltrider. Yes, just very quickly because I think that 
Mr. Blaylock makes a good point in terms of new information 
continuing to evolve. I mean, with the artificial intelligence 
and the data management capabilities that we currently have, 
there is tremendous innovation occurring. But I see it nearly 
every day. And I had a call with the head of the business 
development group at Dana-Farber this morning. She can't get 
any interest in terms of trying to form a new co, trying to 
license it out. If it is a diagnostic, and that innovation is 
relevant to a diagnostic, it is a hot potato, and no one wants 
to touch it.
 Chair Tillis. Well, you all, thank you. Thank you for 
being--that is really what I am concerned about. I want to get 
more in the pipeline, and I am trusting that the ultimate 
decision on whether or not to grant a patent has sufficient 
guardrails. At the same time, I want more innovation. I want 
more cures. I want more AI algorithms. I want more outputs from 
the U.S. economy to maintain our lead.
 We are about to conclude this hearing. I did mention in my 
opening comments, I kind of hope this is the last hearing on 
PERA before a markup. I am going to do everything I can to move 
this bill. So Mr. Blaylock, to your point, I have thoroughly 
appreciated your prior testimony and the experience you bring 
to the table. I am going to do everything I can in cooperation 
with my colleague to move this bill forward and to get a 
markup, and so you should assume that there is at least one 
person who is going to be very focused on this, and therefore, 
it will be moving, and we would appreciate your feedback on how 
to address the concerns that we can.
 This has been another very helpful Committee. We are going 
to keep the record open for a week. We would encourage you all 
to submit any other papers or documentation you would like for 
the record.
 And be on the lookout. I have got to talk with the Ranking 
Member, but I think most of you all that have participated in 
any of our workgroups, I really kind of prefer the work 
sessions to Committee hearings because we can really get into a 
collaborative mode, so be on the lookout for an invitation to 
participate in that as we prepare to gain support and 
ultimately move to markup.
 Thank you all for being here.
 [Whereupon, at 4:45 p.m., the hearing was adjourned.]
 [Additional material submitted for the record follows.]
 
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] 

 A P P E N D I X

The following submissions are available at:

 https://www.govinfo.gov/content/pkg/CHRG-119shrg62725/pdf/CHRG-119shrg
 62725-add1.pdf

Submitted by Chair Tillis:

 American Intellectual Property Law Association (AIPLA), statement 2

 Aronson, Lauren, statement....................................... 4

 Association for Accessible Medicines (AAM), statement............ 8

 BioUtah, letter.................................................. 12

 Council for Innovation Promotion (C4IP), statement............... 13

 Krause, Thomas, background letter................................ 16

 Krause, Thomas, statement........................................ 27

 Lemley, Mark A., statement....................................... 34

 Squires, John A., statement...................................... 40

Submitted by Ranking Member Schiff:

 Aronson, Lauren, statement....................................... 4

 Association for Accessible Medicines (AAM), statement............ 8

 College of America Pathologists (CAP)............................ 47

 Lemley, Mark A., statement....................................... 34

 [all]